Curriculum Vitae: MARY J.C. HENDRIX July 2014 US...

Curriculum Vitae: MARY J.C. HENDRIX July 2014

Personal Data US Citizen

President and Scientific Director Stanley Manne Children’s Research Institute

Ann & Robert H. Lurie Children’s Hospital of Chicago Feinberg School of Medicine Northwestern University 225 East Chicago Avenue, Box 222 Chicago, Illinois 60614-3394 T: 773.755.6528 F: 773.755.6534 E: [email protected] Education

Year (Graduated) Degree Institution Field

1974 B.S. Shepherd College, WV Pre-Med/Biology

1977 Ph.D. George Washington University Anatomy/Cell Biology

Post Graduate Education

Year Degree Institution Field

1977-80 Postdoc Harvard Medical School Cell/Developmental Biology

Honors and Awards 1971 - 1973 Turner Excellence in Science Scholarship, Shepherd College 1975 - 1977 WV American Heart Association/National Capitol Affiliate Student Research Fellowship,

George Washington University, Department of Anatomy 1977- 1980 United States Public Health Service Postdoctoral Research Fellowship, Harvard Medical

School, Department of Anatomy & Cell Biology 1985 - 1994 Commissioner, Arizona Disease Control Research Commission 1986 Dedication of the Captain C.N.G. Hendrix Oceanography Laboratory/U.S.N.A. 1986 Member, American Men and Women in Science 1987 Dean’s List for Excellence in Teaching Basic Sciences, University of Arizona 1988 Proctor and Gamble Cancer Research Lectureship Award 1988 Outstanding Undergraduate Alumnus Award (Shepherd College) 1991 University of Arizona Mortar Board Citation 1992 Louis J. Kettel Medical Student Mentorship Award, University of Arizona 1995 IMMUNO-US Endowed Professorship, St. Louis University 1996 Honorary Doctorate of Science (D.Sc.), Shepherd College, now Shepherd University 1998 Phi Kappa Phi Honor Society 1999 Kate Daum Endowed Research Professorship, The University of Iowa 2001 Medical Student Research Day Speaker, Loyola University School of Medicine 2002 The Coffey Lectureship Award, SBUR, Orlando, Florida 2002 Frank Low Research Lectureship, University of North Dakota 2002 MERIT Award Recipient, National Cancer Institute

mailto:[email protected]

Mary J.C. Hendrix

2003 Distinguished Achievement Award, Celebration of Excellence Among Women, The University of Iowa

2004 Australian Society for Medical Research (ASMR) Lecturer and Medal Recipient 2005 Children’s Research Fund Professorship, Lurie Children’s Hospital (formerly (Medical Research Institute Council Professorship) 2006 Distinguished Women in Medicine and Science Lecturer, Northwestern University

Feinberg School of Medicine 2006 Henry Gray Award, American Association of Anatomists 2006 Voices Take Flight – Service Before Self Award 2007 Co-Chair, Research!America Awards Gala 2007 Chitra Biswas Lectureship, Tufts University School of Medicine 2007 Murray Barr Award, University of Western Ontario 2007 DSR Sarma Lectureship in Oncologic Pathology, University of Toronto 2008 Princess Takamatsu Cancer Research Fund Lectureship, Japan 2010 Pritchett Lectureship Award, University of Alabama 2010 Ruth Sager Memorial Lectureship, Harvard University 2011 Honorary Doctorate of Science (D.Sc.), Lake Forest College 2012 Princess Takamatsu Cancer Research Achievement Award 2012 20th Barnum Museum Lectureship, Tufts University School of Medicine 2012 H Foundation Basic Science Symposium Keynote, Robert H. Lurie Comprehensive

Cancer Center of Northwestern University 2012 43rd Princess Takamatsu International Cancer Symposium Lecturer, Japan 2014 Vision and Impact Award, Regional American Committee for the Weizmann Institute of Science Faculty Appointments University of Arizona, Department of Cell Biology and Anatomy, Tucson, Arizona 1980-1986 Assistant Professor 1986-1991 Associate Professor 1991-1993 Associate Head 1992-1993 Professor 1987-1993 Member, University of Arizona Comprehensive Cancer Center 1990-1993 Member, University of Arizona Heart Center 1984-1993 Graduate Faculty Member, Department of Microbiology & Immunology University of California, San Francisco, California 1981-1985 Adjunct Assistant Professor, School of Medicine, Pathology Department Saint Louis University Health Sciences Center, St. Louis, Missouri 1994-1996 Director, Pediatric Research Institute (Cardinal Glennon Children’s Hospital) 1995-1996 IMMUNO-US Endowed Professor in Pediatric Research, Department of Pediatrics The University of Iowa, Iowa City, Iowa 1996 - 2004 Head, Department of Anatomy and Cell Biology, Carver College of Medicine 1997 - 2004 Associate Director of Basic Research, Holden Comprehensive Cancer Center at The University of Iowa 1999 - 2004 Deputy Director, Holden Comprehensive Cancer Center at The University of Iowa 1999 - 2004 Kate Daum Endowed Research Professor, The University of Iowa 1996 - 2004 Graduate Faculty Member, Molecular Biology Program

Mary J.C. Hendrix

Northwestern University, Chicago, Illinois 2004 - present President and Scientific Director, Stanley Manne Children’s Research Institute of Ann & Robert H. Lurie Children’s Hospital of Chicago 2004 - present Professor, Robert H. Lurie Comprehensive Cancer Center 2008 - present Member, Center of Reproductive Science Administrative Appointments 1991 -1993 Associate Head, University of Arizona, Department of Cell Biology and Anatomy 1994 -1996 Director, Pediatric Research Institute (Cardinal Glennon Children’s Hospital) 1996 - 2004 Head, Department of Anatomy and Cell Biology, Carver College of Medicine 1997 - 2004 Associate Director of Basic Research, Holden Comprehensive Cancer Center at The University of Iowa 1999 - 2004 Deputy Director, Holden Comprehensive Cancer Center at The University of Iowa 2004 - present President and Scientific Director, Stanley Manne Children’s Research Institute of

Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Summary of Teaching Experience (Most Recent) Teaching Assignments 1996 - 2003 Human Organ Systems 50:240 (Medical and Graduate) 1996 - 2003 Seminars in Cancer Biology 60:207 (Graduate) 1997 - 2003 Cellular and Molecular Biology of Cancer 69:288/77:288 (Graduate) 1997 - 1998 Principles of Human Anatomy 60:001/60:010 (Undergraduate) 1999 - 2003 Survival Skills for a Research Career 60:204 (Graduate) 2000 - 2003 Experimental Approaches to Human Disease 60:208 (Graduate) 2001 - 2003 Pathogenesis of Major Human Diseases 69:270 (Graduate) 2001 - 2003 Human Genome Issues, Science and the Arts 033:153 (Undergraduate) 2001 - 2003 Ethics in Science Seminars (Medical) Graduate Ph.D. Students (Major Advisor) Judy Ulreich 1980-1987 Surgery, University of Arizona Kurt R. Gehlsen 1982-1986 Cell Biology & Anatomy, University of Arizona Rebecca Woods 1984-1989 Cell Biology & Anatomy, University of Arizona Christopher Greef 1985-1987 Cell Biology & Anatomy, University of Arizona Sandra J. Bavacqua 1985-1989 Cell Biology & Anatomy, University of Arizona Padma Sundareshan 1986-1990 Cell Biology & Anatomy, University of Arizona Phillip Saba 1986-1993 Cell Biology & Anatomy, University of Arizona Michelle Davis 1988 Cell Biology & Anatomy, University of Arizona Maria Bishop 1988 Cell Biology & Anatomy, University of Arizona Adrian Winters 1989-1993 Cell Biology & Anatomy, University of Arizona Hanifa Jones 1991-1994 Cell Biology & Anatomy, University of Arizona Catherine Frye 1992-1995 Cell Biology & Anatomy, University of Arizona Daniel Nieva 1994-1999 Anatomy and Cell Biology, University of Iowa Jun Luo 1996-1999 Anatomy and Cell Biology, University of Iowa Navesh Sharma 1996-2000 Anatomy and Cell Biology, University of Iowa Angela Hess 1998-2002 Anatomy and Cell Biology, University of Iowa Robert Bhatty 2000-2002 Anatomy and Cell Biology, University of Iowa Preeda Chunthapong 1998-2003 Anatomy and Cell Biology, University of Iowa Valerie Odero 1999-2003 Molecular Biology Program, University of Iowa Lisa Lee 2001-2005 Anatomy and Cell Biology, University of Iowa Stacey Payne 2003-2006 Bioscience Program/Anatomy & Cell Biology,

Mary J.C. Hendrix

University of Iowa Caleb Bailey 2002-2006 Bioscience Program/Anatomy & Cell Biology,

University of Iowa Postdoctoral Fellows, Visiting Scholars and Research Faculty Bruce Persky 1981-1983 Postdoctoral Associate Anita S-F Chong 1986-1988 Postdoctoral Associate Richard Seftor 1986-1990 Postdoctoral Associate Linda Meade-Tollin 1987-1990 Postdoctoral Associate Karin H. Yohem 1988-1990 Postdoctoral Associate Zhila Khalkhali-Ellis 1994-1996 Postdoctoral Associate Margaret Ruiz 1995-1996 Postdoctoral Associate Dawn Kirschmann 1995-1996 Postdoctoral Associate Zhila Ellis 1994-present Research Associate Professor Joseph De Larco 1995-1997 Research Scientist Margaret Ruiz 1995-1996 Minority Research Investigator Dawn Kirschmann 1995-present Research Associate Professor Patricia Thomas 1996-1998 Minority Faculty Investigator Richard E.B. Seftor 1996-present Research Professor Jackie Bickenbach 1997-1998 Associate Research Scientist Andrew Maniotis 1997-2000 Assistant Research Scientist Gina M. Nelson 1997-1999 House Staff IV/Resident Nancy Arbour 2000-2001 Assistant Research Scientist Naira Margaryan 2001-present Research Scientist Sumaria Amir 2001-2004 Postdoctoral Scholar Angela Hess 2002-2007 Postdoctoral Fellow, Research Assistant Professor Daisy van der Schaft 2002-2003 Visiting Postdoctoral Scholar Shaon Datta 2003-2005 Master’s Student/Dental Scholar Lynne Postovit 2004-2007 Postdoctoral Scholar Zoe Demou 2005-2007 Postdoctoral Scholar Mitchell Lawrence 2006 Fulbright Scholar Caleb Bailey 2006-2008 Postdoctoral Fellow Luigi Strizzi 2007-present Research Assistant Professor Rocky Pramanik 2008-2009 Senior Research Scientist Katharine Hardy 2008-present Postdoctoral Fellow Anna Hooijkaas 2009 Visiting Graduate Student Scholar Gina Kirsammer 2009-present Postdoctoral Fellow Thomas Bodenstine 2010-present Postdoctoral Fellow Mentored Clinician Scientists in Hendrix Laboratory Diana Mahurin, MD 1997-1998 The University of Iowa Maleah Grover-McKay, MD 1997-1998 The University of Iowa Joanne Tobacman, MD 1998-2000 The University of Iowa Anil Sood, MD* 1998-2002 The University of Iowa Anuja Dokras, MD, PhD* 1999-2006 The University of Iowa Galen Schneider, DDS, PhD 1999-2004 The University of Iowa Doug Trask, MD, PhD 2000-2004 The University of Iowa Di Lu, MD 2001-2003 The University of Iowa Mei-Yu Hsu, MD, PhD 2003-2004 The University of Iowa Daniel Abbott, MD 2006-2008 Northwestern University Colleen Morrison, MD* 2008-2010 Northwestern University (*Denotes faculty with mentored training awards with Dr. Hendrix)

Mary J.C. Hendrix

Committee Service University of Arizona 1980 - 1981 Admissions Committee, Interviewer 1980 - 1993 Minority Recruitment Program 1981 - 1984 Admissions Committee, Member 1981 - 1983 Institutional Cancer Grant Review Committee 1981 - 82; 88 - 89 Recruiting Committees (Anatomy/Cancer Center), (Anatomy; Chairperson) 1981 - 1993 Cancer Biology Training Grant Committee: Progress Committee (Chairperson 1983-1988) Cancer Biology Executive Committee Pre/Postdoctoral Selection Committee (Chairperson 1988-1993) Admissions Committee (Chairperson 1991-1993) 1981 - 1993 Medical Student Research Training Program (Associate Director) 1982 - 1985 Honor and Awards Committee (Chairperson) 1982 - 1985 Cancer Center Executive Committee 1982 - 1993 WISE (Women in Science & Engineering) 1983 - ‘86; ‘91-‘93 Seminar Committee 1984 - 1991 Graduate Studies Committee 1985 - 1986 Ad Hoc GPEP Subcommittee (for Curriculum Committee) 1985 - 1993 Human Subjects Committee (Chairperson) 1986 - 1987 Code of Scholastic Conduct Committee 1986 - 1987 LCME Research Subcommittee 1986 - 1989 Intercollegiate Athletic Committee 1986 - 1993 Heart Center Planning Committee 1987 - 1988 Search Committee, Department of Molecular and Cellular Biology 1987 - 1988 Academic Review Committee for Pathology 1987 - 1990 Electron Microscopy Committee (Chairperson) 1987 - 1990 Cell Biology Curriculum Committee (Chairperson) 1988 - 1989 Recruiting Committee 1988 - 1990 Molecular and Cell Biology Curriculum Subcommittee 1988 - 1990 EM User Group Committee 1988 - 1990 Research Policy Committee 1988 - 1991 Nominating Committee (Collegiate) 1988 - 1993 M.D./Ph.D. Steering Committee 1989 - 1991 Committee on Ethics and Commitment 1989 - 1991 Small Grants Review Subcommittee (Chairperson) 1989 - 1993 Advisory Committee to the Vice-President for Research 1990 - 1993 Heart Center Search Committee (Chairperson) 1991 - 1993 Dean’s Research & Development Committee 1991 - 1993 Executive Committee (Collegiate) 1992 - 1993 Executive Committee (Medical Microbiology & Immunology) 1992 - 1993 Dean’s Teaching Scholarship Program Steering Committee 1993 Promotions and Tenure Committee (Departmental Chairperson) State of Arizona 1983 - 1984 Program Director, Arizona Society of Electron Microscopy and Microbeam

Analysis (A.S.E.M.M.A.) 1985 - 1994 Commissioner, Arizona Disease Control Research Commission (ADCRC) (Research Advisory Committee to the Governor of Arizona) 1992 Member, Executive Director Search Committee (for ADCRC)

Mary J.C. Hendrix

Saint Louis University Health Sciences Center 1994 Glennon Magazine Editorial Board 1994 -1996 Pediatric Research Institute Search Committee (Chairperson) Faculty Status Committee 1994 -1996 Pediatric Administrative Advisory Committee Research Advisory Council (Chairperson) Vice-Chair Search Committee 1994 -1996 Research Planning Committee Internal Medicine Search Committee 1994 -1996 Transgenics Committee 1995 -1996 Pediatric Research Institute Executive Committee (Chairperson) 1995 -1996 Associate Vice President for Research Search Committee 1995 -1996 OB/GYN Chairman Search Committee (Chairperson) 1995 -1996 Strategic Planning Committee The University of Iowa 1996 - 1997 Research Week Committee 1996 - 1998 Biochemistry Head Search Committee 1996 - 2003 Cancer Center/UIHC Speakers Bureau 1996 - 2001 Medical Scientist Training Program Executive Committee 1996 - 2003 Cancer Center Executive Committee 1996 - 2003 Cardiovascular Center Executive Committee 1996 - 2003 Leader, Molecular Mechanisms of Metastasis Program 1997 - 2003 Central Microscopy Research Facility Advisory Committee 1997 - 2000 IMAC, Iowa Multidisciplinary Arthritis Center 1997 - 2000 Collegiate Campaign Leadership Team 1997 - 2003 Helen C. Levitt Endowed Annual Visiting Professorship Advisory Committee 1997 - 2003 Molecular Biology Interdisciplinary Program (Faculty Member) 1998, 2003 Mini-Med School/Cancer Center 1998 - 2003 AMWA Mentor for Medical Students 1998 - 2003 Translational Research Endowed Chair Search Committee 1998 - 2003 NIDR Internal Advisory Committee 1998 - 2000 Cancer Center Research Review Committee 1998 - 2003 Illumine Advisory Board 1999 - 2001 HHMI Advisory Committee 1999 - 2002 Medical Student Research Advisory Committee 1999 - 2001 Research Advisory Council (Co-Chair) 2000 - 2003 Task Force on Animal Imaging 2000 - 2003 UI Gene Therapy Center Executive Committee 2000 - 2001 Associate Director for the Administration Search Committee 2001 - 2003 College of Medicine Faculty Practice Planning Board 2001 - 2003 Research Advisory Council (Chair) 2002 - 2003 Cancer Genetics Search Committee 2002 - 2003 Medical Oncologist Search Committee 2002 College of Medicine Dean’s Search Committee 2002 - 2003 College of Medicine Research Week Committee (Co-Chair) 2002 - 2003 Holden Chair in Cancer Biology Search Committee (Chair) Northwestern University and Ann & Robert H. Lurie Children’s Hospital of Chicago 2004 - present Board Member, Stanley Manne Children’s Research Institute (Executive, Finance

and Nominating Committees) 2004 - 2006 Supra-Departmental Search Committee, Feinberg School of Medicine

Mary J.C. Hendrix

2004 - present Robert H. Lurie Comprehensive Cancer Center Executive Committee 2004 - present Innovative Technology Advancement Committee, Stanley Manne Children’s

Research Institute 2004 - present Medical Administrative Advisory Committee, Lurie Children’s Hospital 2004 - 2005 Strategic Planning Subcommittee, Robert H. Lurie Comprehensive Cancer Center 2004 – 2010 Center for Genetic Medicine Executive Committee 2004 - 2010 Dean’s Research Council, Feinberg School of Medicine 2004 - 2006 Northwestern University Roadmap Committee 2005 - present Department of Pediatrics APT Committee 2005 - 2010 Internal Scientific Advisory Committees for Breast and Prostate SPOREs 2005 - 2008 Northwestern University Office of Research Advisory Committee 2005 - present Internal Grant Review Committee, Robert H. Lurie Comprehensive Cancer Center

American Cancer Society-Institutional Research Grant 2005 - present External Advisory Board, Developmental Signaling Pathways: Genes and

Environment Program Project, Northwestern University’s Feinberg School of Medicine

2005 - 2010 Regenerative Medicine Executive Steering Committee 2005 - 2006 RNAi Library Task Force 2005 - present Board Member, Lurie Children’s Medical Center (Executive Committee) 2006 - present Northwestern University Skin Disease Research Center Pilot and Feasibility

Review Committee 2006 - present Northwestern University Clinical and Translational Research Advisory Council 2006 - 2011 Stem Cell Center of Excellence Executive Committee, Feinberg School of Med. 2006 - present Northwestern University Committee on Human Stem Cell Research 2006 - present Advisory Board for Epigenomics Core 2006 - 2007 Research Campus Coordination Committee, Co-Chair 2007 - present Executive Committee for P30 Multiphoton Facility, Member 2007 - present Stanley Manne Children’s Research Institute-FSM Task Force on Research

Synergy, Co-Chair 2008 – 2013 Project Director, XenoBase: A Translational Research Data Management Tool 2009 - present Board Member, Lurie Children’s Hospital of Chicago Foundation 2009 - 2011 Chair, Research Strategic Planning Committee for Lurie Children’s Medical Center 2010 - present Internal Advisory Board for Translational Center for Fast-tracking Nanomaterials 2011 - present Northwestern University Medicine Research Group 2013 - present Northwestern University Research Building Faculty Advisory Committee 2013 - present Northwestern Medicine Dixon Translational Research Council 2014 - present Robert H. Lurie Comprehensive Cancer Center Director Search Committee,

Member Professional and Scientific Activity 1984 - present Legislative Alert Committee for American Society for Cell Biology 1985 - 1986 Organizing Committee, International Pigment Cell Society Meeting 1986 - 1989 National Advisory Council for Young Anatomists (Vice-Chairman) 1986 - 1988 Nominating Committee for American Association of Anatomists (AAA) 1986 - 1989 Langman Award Committee for AAA (Chairperson) 1989 - 1991 Consultant for Strategic Technologies International 1989 - 1994 Executive Committee for AAA 1991 - 1992 Public Affairs Subcommittee for AAA 1991 - 1996 Research Dissertation Reviewer for AAA 1991 - 1994 Cell Biology Scientific Program Organizer for AAA (FASEB Theme Rep) 1991 - 1993 Nominating Committee for International Pigment Cell Society

Mary J.C. Hendrix

1992 - 1994 Strategic Planning Committee for AAA 1992 - 1998 Consultant, Integrated Market and Technology Assessments, Inc. 1993 - 1994 Executive Committee for International Lymphology Society 1994 - 1996 Program Secretary for AAA 1994 - 1995 Vice-President for AAA 1994 - 1996 National Association of Children’s Hospitals & Related Institutions Committee 1994 - 2003 Consultant, Arizona Disease Control Research Commission 1995 - 1996 Board of Directors, AMC Cancer Research Center, St. Louis Region 1996 Guest Editorial Organizer of Cancer and Metastasis Reviews (IF issue) 1997 - 2002 FASEB (Federation of American Societies for Experimental Biology) Board of

Directors 1997 - 2000 Councilor, Association of Anatomy, Cell Biology, Neurobiology Chairpersons 1998 - 2002 Program Committee for AACR 1998 - 2004 Board of Directors of the Metastasis Research Society 1999 - 00; 02-03 National Search Committee for Editor-in-Chief of the Am. J. Pathology 1999 - 2000 President-Elect, FASEB (Federation of American Societies for Experimental

Biology) 1999 - 2004 Member, Shepherd College Foundation Board of Directors 2000 - 2001 President, Federation of American Societies for Experimental Biology 2000 - present Member, Scientific Advisory Board, Lympathic Research Foundation 2000 - 2002 Chair, Nominating Committee for AAA 2001 - 2003 Consultant, Avolix, Inc. 2001 – 2004 Society for Regenerative Medicine & Stem Cell Biology Board of Directors 2001 - 2002 NIH Boundary II Review Panel for Oncological Sciences Study Sections (Chair) 2001 - 2010 External Advisory Committee, USC Cancer Center 2001 - 2004 ASBMB Public Affairs Advisory Committee 2001 - 2002 Past-President, FASEB 2001 - 2003 Member, Minorities/Opportunities Committee; Membership Committee, AACR 2001 - 2005 Board of Directors of PRIM&R (Public Responsibility in Medicine and Research) 2001 - 2003 Consultant, CancerVax Corporation 2001 - 2003 Consultant, InnaPharma, Inc. 2002 - 2009 External Advisory Committee, University at Albany Center for Comparative

Functional Genomics 2002 - 2003 President-Elect, Association of Anatomy, Cell Biology, & Neurobiology

Chairpersons (AACBNC) 2003 - 2004 President, Association of Anatomy, Cell Biology, & Neurobiology Chairpersons 2002 - 2004 Representative, FASEB Federal Funding Consensus Conference 2002 - 2004 Member, Extramural Advisory Board for the University of Nebraska Med Center 2002 - 2004 Member, National Advisory Council for Annenberg Center for Health Sciences 2002 - 2004 Chair, Capital Campaign for FASEB 2002 Participant, Novartis Research Retreat on Molecular Mechanisms of Metastasis 2002 - 2005 Public Affairs Committee, American Association of Anatomists 2002 - present External Advisory Committee for Mayo Cancer Center Pancreatic SPORE 2003 - 2009 Member, AAMC Advisory Panel on Research 2003 – 2007 Member, National Advisory Council for Human Genome Research 2003 - present Advisory Committee, Charles L. Witte Professorship in Surgery, Univ. of Arizona 2003 NIH Subcommittee, 2003 FASEB Federal Funding Consensus Conference 2003 Invited Participant, NCI Tumor Microenvironment Think Tank 2003 - 2004 NCI Research Project Grant Working Group 2003 - 2005 External Advisory Committee, San Antonio Cancer Institute 2004 - 2010 Member, Council for American Society for Investigative Pathology 2004 - 2012 NCI Board of Scientific Advisors

Mary J.C. Hendrix

2004 - 2005 External Advisory Committee, Mary Babb Randolph Cancer Center at West Virginia University

2005 – present Co-Founder, Virtual Naval Hospital 2004 - 2010 External Advisory Committee, M.D. Anderson Cancer Center Breast SPORE 2004 - 2008 Public Affairs Committee, American Society for Biochemistry & Molecular Biology

(Chair; 2007 - 2008) 2005 - 2007 Member, American Society for Cell Biology Nominating Committee 2005 - 2007 Member, Scientific Advisory Board, LaJolla Institute for Molecular Medicine 2005 - present Member, Research!America Board of Directors, and Advocacy Awards Selection 2005 - present Member, AACR Awards Committee/Grants Committee 2006 - present Member, Board of Directors for Annenberg Center for Health Sciences at Eisenhower Medical Center 2006 - 2010 Member, AAMC Distinguished Research Award Review Committee 2006 - 2008 Chair, Fellows Selection Committee for AAA 2006 - 2007 External Advisory Board, University of Utah Children’s Health Research Center 2006 - 2010 NIH Genome Atlas Group; TARGET Subcommittee 2006 NIH Roadmap Consultation Group 2006 - 2012 External Advisory Board, Duncan Cancer Center at Baylor College of Medicine 2006 - present External Advisory Committee, Center of Biomedical Research Excellence, University of Kansas Medical Center 2007 - 2008 Member, Nominating Committee, American Society for Investigative Pathology 2007 - 2010 AACR President’s Circle Leadership Council 2007 National Science Advisory Board for Biosecurity Working Group 2007 - present Member, American Association of Anatomists Henry Gray/Lippincottt Williams &

Wilkins Scientific Achievement Award, AAA/Wiley A.J.Ladman Exemplary Service Award, and Honorary Membership Committees

2007 NIH Director’s Pioneer Awards Interview Committee 2007 - 2008 Member, Board of Directors for Campaign for Medical Research 2007 - present Member, Melanoma Research Foundation Scientific Advisory Committee 2007 - present Member, Board of Directors for The Chicago Council on Science & Technology 2007 - 2010 Member, NIH Council of Councils (Oversight Committee for the Office of Portfolio Assessment and Analysis, Congressionally Mandated) 2008 - 2009 Member, NIH Research Condition and Disease Categorization (RCDC) Technical

Review Working Group 2008 - 2009 Member, External Advisory Board for the Child Health Institute of New Jersey 2008 - present Member, Tumor Microenvironment Working Group 2008 – 2013 Treasurer, Research!America 2008 - 2010 Chair, Research!America Membership Committee 2008 - present Member, External Advisory Board, Avolix Pharmaceuticals 2009 - present Member, American Cancer Society Research & Medical Affairs Strategic

Operations Advisory Panel 2010 - 2012 Member, AACR WICR Charlotte Friend Memorial Lectureship Selection Cmte. 2010 - 2014 Member, AACR Finance and Audit Committee 2013 - present Member, AACR Women in Cancer Research Council 2013 Chair, AACR Princess Takamatsu Memorial Lectureship Award Committee 2014 - present Member, Board of Directors for National Disease Research Interchange (NDRI); Scientific Advisor U.S. Congressional Testimony 2000 Senate Labor HHS Appropriations Subcommittee (NIH Budget) 2001 House Labor HHS Appropriations Subcommittee (NIH Budget) 2001 House Appropriations Subcommittee (NSF Budget)

Mary J.C. Hendrix

2001 Senate Subcommittee on Defense Appropriations (DOD Budget) 2001 Senate Hearing on Human Embryonic Stem Cell Research 2009 House Labor HHS Appropriations Subcommittee (NIH Budget) Illinois State Congressional Testimony 2004 Senate Health & Human Services Committee Hearing on Human Embryonic Stem Cell Research 2004 Council of Women Legislators Presentation on Human Embryonic Stem Cell Research 2005 Tutorials on Human Embryonic Stem Cell Research for Bipartisan House Stem Cell Forum 2006 Tutorials on Human Embryonic Stem Cell Research for Illinois Legislators Grant Review Service 1985 - 1994 Arizona Disease Control Research Commission Grant Review Committee 1985 - 2000 NSF, Cell Biology Program (Ad hoc) 1990 - 1995 American Cancer Society Cell Biology Study Section 1992 NIH/NCI Breast SPORE Study Section 1992 NIH/NCI Outstanding Investigator Study Section 1989 - 2004 NIH/NCI Site Visit Review Committee (Ad hoc) 1993 - 1995 NIH/NCI Pathology B Study Section (Ad hoc) 1994 NIH/NCI Special Breast and Prostate Study Section 1994 - 2003 NIH/NCI Special Emphasis Panel Study Section Teleconference 1995 - 1999 NIH/NCI Pathology B Study Section (*Chair 1998-1999) 1995 - 1999 NIH Intramural Review Committee for Biological Sciences

USAMC Breast Cancer Review Panel (*Chair - Pathobiology 2) 2000 NCI Intramural Special Review Panel 2000 - 2004 Dutch Cancer Society; Israel Science Foundation; Italian Cancer Society 2003 - 2004 NIH/NCI Tumor Microenvironment Study Section (Chair) 2009 - 2010 Member, AACR Stand Up to Cancer Innovative Research Grants Committee 2009 - 2010 Susan G. Komen Scientific Review Committee, Chair 2010 - present Melanoma Research Foundation Grant Review Committee, Member 2011 - present NIH Transformational RO1 Review Committee, Editor 2011 DOE Special Review Panel 2011 - present Susan G. Komen Scientific Review Committee, Member 2011- present NIH Pioneer Award Review Committee, Member Professional Societies American Association for the Advancement of Science American Society for Cell Biology American Association of Anatomists American Society for Investigative Pathology American Society for Biochemistry and Molecular Biology American Association for Cancer Research Metastasis Research Society International Lymphatic Society Editorial Service 1993 - 1998 Anatomical Record, Editorial Board 1996 - 2009 Pathology Oncology Research, US Regional Editor (2010-present; Ed. Consultant) 1999 - 2004 Cancer Letters, Editorial Board 2000 - 2007 Clinical Cancer Research, Editorial Board; Associate Editor, 2000-2007

Mary J.C. Hendrix

2001 - 2007 Cancer and Metastasis Reviews, Editorial Advisory Board 2001 - present Cancer Biology and Therapy, Editorial Board 2002 - present International Journal of Oncology, Editorial Academy 2002 - present Lymphatic Research and Biology, Editorial Board 2003 - 2012 Clinical Proteomics, Editorial Board 2003 - present Journal of Cellular Biochemistry, Associate Editor 2003 - present Cancer Research, Associate Editor 2003 - present American Journal of Pathology, Editorial Board; Associate Editor, 2004-2008 2003 - present Lymphology, Editorial Board 2007 - present Cancer Microenvironment, Editorial Board 2008 - present Chinese Journal of Cancer, Editorial Board 2009 - present World Journal of Stem Cells, Editorial Board 2009 - 2012 Cancer Prevention Research Organizer or Co-Organizer of National/International Meetings "Model Systems for Melanocytes and Melanoma", International Pigment Cell Meeting, Tucson, Arizona, 1986 "Experimental Metastasis: Designing New Research Strategies", NIH/NCI Workshop, Washington, D.C., 1987 "Cell Biology Symposia I and II", American and Japanese Associations of Anatomists, San Diego, California, 1993 FASEB Program Organization Committee, Washington, D.C., 1994-1998 "Cancer Biology Workshop", Panama City, Florida, 1996 "Breast Cancer Workshop", Keystone, Colorado, 1997 "International Prostate Cancer Meeting", Iowa City, Iowa, 1998; 2002 Vice-Chair of the Gordon Conference on Chemically Modified Tetracyclines, 1999 "Academic, Government, Industrial Partnership Conference", Washington, D.C., 2001 “Research Presentation Skills”, EB2003, San Diego, California, 2003 “Essentials in Bioterrorism Research Workshop”, PRIM&R, Washington, D.C., 2003 “Remarkable Role of the Microenvironment in Development and Disease Pathogenesis Symposium”, EB2004, Washington, D.C. 2004 “First International Symposium on Cancer Metastasis and the Lymphovascular System: Basis for Rational Therapy”, San Francisco, California 2004 “Angiogenesis Therapy”, Mayo Clinic, Minnesota, 2004; 2006 “Bea Schriesheim Ovarian Cancer Symposium”, Chicago, Illinois, 2005, 2006 “Cell Microenvironment in Development and Cancer”, EB 2007, Washington, D.C. “Second International Symposium on Cancer Metastasis and Lymphovascular System”, San Francisco, California, May 2007 Keystone Symposia on “Extrinsic Control of Tumor Genesis and Progression”, Vancouver, British Columbia, March 2009 Current Research Grants and Contracts (Total Costs) 2R37 CA59702-10 (Hendrix) (MERIT Award) 5/1/02 - 2014 NIH/National Cancer Institute $4,425,000 ($100,000 supplement 5/1/04 – 4/30/05) Endothelial Transdifferentiation of Invasive Tumor Cells The long-term objective of this project is to determine the functional significance of VE-cadherin expression in human melanoma tumor cells engaged in endothelial transdifferentiation and vasculogenic mimicry.

1R01 CA121205-01 (Hendrix) 7/1/07 - 2014 NIH/National Cancer Institute $1,824,127 3RO1 CA121205-02S1 $ 9,700 (ARRA Student Supplement, Summer 2009)

Mary J.C. Hendrix

3RO1 CA121205-03S1 $ 478,020 (ARRA Collaborative Grant; 8/1/09-7/31/11) Epigenetic Effect of the Microenvironment on Stem Cell Plasticity and Function This project tests the central hypothesis that the embryonic microenvironments associated with hESCs and chick neural crest-rich region(s) -- contain informational cues with the potential to epigenetically reprogram the genotype and phenotype of human metastatic multipotent melanoma cells exposed to them.

U54 Physical Science - Oncology Center (O’Halloran) 9/1/09 - present NIH/National Cancer Institute $330,750 (Direct costs) The Coding, Decoding, Transfer, and Translation of Information in Cancer Project: Dynamic Nucleosome Signatures in Cancer Development and Epigenetic Memory; Hendrix, PI, Subcontract This project utilizes a 3-D tumor cell-microenvironment model to assess epigenetic reprogramming via nucleosome signatures.

NCI U54 CA151880 (Mirkin) Center of Cancer Nanotechnology Excellence (NU-CCNE) 2/1/12 - present Pilot Project: Hendrix, PI $52,500 (Direct costs) Delivery of hLefty Nanoconjugate to Suppress Tumorigenicity and Metastasis This work will test whether hLefty nanoconjugates can target and down-regulate Nodal-expressing, aggressive human melanoma cells and result in less aggressive and less metastatic cells.

StableBody Technologies, Inc. 4/01/13 - present Contract: Hendrix, PI $1,500,000 (Direct costs) This project advances the study of targeting Nodal-positive tumor cells for cancer therapy.

TaiRx 4/01/14 – present Contract: Hendrix, PI $152,400 (Direct costs) This project assesses the underlying molecular mechanisms affected by a new anti-cancer agent (TRX-818). _________________________________________________________________________________ Little Heroes Pediatric Cancer Foundation 9/1/10 – 8/31/15 Hendrix, PI $250,000 (Direct costs) This study measures Nodal in various stages of neuroblastoma. Submitted applications are available upon request

Scholarly Productivity A. Refereed Journal Articles 1. Hendrix MJC and Morse DE. Atrial Septation, I. Scanning electron microscopy in the chick. Dev

Biol 57:345-363, 1977. 2. Linsenmayer TF, Hendrix MJC and Little CD. Production and characterization of a monoclonal

antibody to chick type I collagen. Proc Natl Acad Sci 76:3703-3707, 1979. 3. Linsenmayer TF and Hendrix MJC. Monoclonal antibodies to connective tissue macromolecules:

Type II collagen. Biochem Biophys Res Commun 92:440-446, 1980.

Mary J.C. Hendrix

4. Morse DE and Hendrix MJC. Atrial Septation, II. Formation of the foramina secunda in the chick.

Dev Biol 78:25-35, 1980. 5. Hendrix MJC, Hay ED, Von der Mark K and Linsenmayer TF. Immunohistochemical localization

of collagen types by electron microscopy in the chick cornea and tibia. Invest. Ophthal Vis Sci 22(3):359-375, 1982.

6. Persky B, Thomson SP, Meyskens FL, Jr. and Hendrix MJC. Methods for evaluating the

morphological and immunohistochemical properties of solid tumor colonies grown in soft agar. In Vitro 18:929-936, 1982.

7. Persky B, Peters EM, Gehlsen KR, Sorrentino JM, Meyskens FL, Jr. and Hendrix MJC. Scanning

and transmission electron microscopic evaluation of human melanoma cells treated with Adriamycin and Actinomycin D. Scan Elect Micros II:983-995, 1983.

8. Kischer CW and Hendrix MJC. Fibronectin in hypertrophic scars and keloids. Cell and Tissue

Res 231:29-37, 1983. 9. Persky B, Meyskens FL, Jr. and Hendrix MJC. Diagnostic electron microscopy for amelanotic

melanoma: Correlation of patient biopsy, soft agar assay, and xenograft. J Path 141:17-28, 1983. 10. Loeber C, Goldberg SJ, Sahn DJ and Hendrix MJC. Dynamic mammalian cardiogenesis:

Investigated by high resolution ultrasound in the guinea pig. Circulation 68:841-845, 1983. 11. Sorrentino JM and Hendrix MJC. EGF receptor binding studies in endometrial cell culture. Life

Sciences 34:1769-1774, 1984. 12. Wong M, Hendrix MJC, Von der Mark K, Little CD and Stern R. Collagen in the egg shell

membranes of the hen. Dev Biol 104:28-36, 1984. 13. Hendrix MJC, Wagner HN, Jr., Thomson SP, Brotherman AR and Lindell TJ.

Immunohistochemical localization of Actinomycin D in human melanoma tumor cells. Anticancer Res 4:97-102, 1984.

14. Gehlsen KR, Wagner HN and Hendrix MJC. Membrane invasion culture system (MICS). Med

Instrumentation 18:268-271, 1984. 15. Hendrix MJC. A morphological characterization of melanoma tumor cell interaction with a

basement membrane model in the absence and presence of an anticancer agent. Scan Elect Micros IV:1973-1982, 1984.

16. Hendrix MJC, Brailey JL and Shenker L. SEM-Dissection of a human embryo derived from an

ectopic pregnancy. Early Human Dev 18:3782-3789, 1985. 17. Hall J, Tseng SCG, Timpl R, Hendrix MJC and Stern R. Collagen types in fibrosarcoma; absence

of type III collagen in reticulin. Human Path 16:439-446, 1985. 18. Hendrix MJC, Gehlsen KR, Wagner HN, Jr. Rodney SR, Misiorowski RL and Meyskens FL, Jr. In

vitro quantitation of melanoma tumor cell invasion. Clin Exp Metas 3:221-233, 1985.

Mary J.C. Hendrix

19. Gehlsen KR and Hendrix MJC. In vitro assay demonstrates similar invasion profiles for B16F1 and B16F10 murine melanoma cells. Cancer Letters 30:207-212, 1986.

20. Ahmann FR, Woo L, Trent J and Hendrix MJC. The growth in semisolid agar of prostate cancer

cells obtained from bone marrow aspirates. Cancer Res 46:3560-3564, 1986. 21. Brower DL, Piovant M, Salatino R, Brailey J and Hendrix MJC. Identification of a specialized

extracellular matrix component in Drosophila imaginal discs. Devel Biol 119:373-381, 1987. 22. Way D, Hendrix MJC, Witte M, Witte C, Nagle R and Davis J. Lymphatic endothelial cell line from

a recurrent retroperitoneal lymphangioma. In Vitro Cell Devel Biol 23:647-652, 1987. 23. Nagle RB, Witte MH, Martinez AP, Witte CL, Hendrix MJC, Way D and Reed K. Factor VIII-

associated antigen in human lymphatic endothelium. Lymphology 20:20-24, 1987. 24. Persky B, Huerta CC and Hendrix MJC. Morphological characterization of cellular and

extracellular components of 7,12 dimethylbenz[a]anthracene induced melanoma tumor. J Exp Path 68:493-499, 1987.

25. Gehlsen KR and Hendrix MJC. Invasive characteristics of avian neural crest cells in vitro.

Pigment Cell Res 1:16-21, 1987. 26. Hendrix MJC, Seftor EA, Seftor REB and Fidler IJ. A simple quantitative assay for studying the

invasive potential of high and low human metastatic variants. Cancer Letters 38:137-147, 1987. 27. Bevacqua SJ, Greeff CW and Hendrix MJC. Cytogenetic evidence of gene amplification as a

mechanism for tumor cell invasion. Som Cell Molec Biol 14:83-91, 1988. 28. Dorr RT, Bozak KA, Shipp NG, Hendrix MJC, Alberts DS and Ahmann F. In vitro rat myocyte

cardiotoxicity model for antitumor antibiotics using adenosine triphosphate/protein ratios. Cancer Res 48:5222-5227, 1988.

29. Loeber CP, Hendrix MJC, Diez de Pinos S and Goldberg SJ. Trichloroethylene: A cardiac

teratogen in developing chick embryos. Pediatr Res 24:740-744, 1988. 30. Cress AE, Kurath KM, Hendrix MJC and Bowden GT. Nuclear protein organization and the repair

of radiation damage. Carcinogenesis 10:939-943, 1989. 31. Persky B, Meyskens FL, Jr. and Hendrix MJC. Immunohistochemical and ultrastructural study of

human melanoma colonies grown in soft agar. Am J Anat 184:212-224, 1989. 32. Welch DR, Lobl TJ, Seftor EA, Wack PJ, Aeed PA, Yohem KH, Seftor REB and Hendrix MJC.

Use of the Membrane Invasion Culture System (MICS) as a screen for anti-invasive agents. Int J Cancer 43:449-457, 1989.

33. Nakajima M, Lotan D, Baig MM, Carralero RM, Wood WR, Hendrix MJC and Lotan R. Inhibition

by retinoic acid to type IV collagenolysis and invasion through reconstituted basement membrane by metastatic rat mammary adenocarcinoma cells. Cancer Res 49:1698-1706, 1988.

34. Yohem KH, Seftor EA, Meyskens FL, Jr. and Hendrix MJC. Cloning efficiency of human

melanoma cells improves after invasion through a reconstituted basement membrane. Cancer Letters 45:135-143, 1989.

Mary J.C. Hendrix

35. Hendrix MJC, Seftor EA, Seftor REB, Misiorowski RL, Sundareshan P, Saba PZ and Welch DR.

Tumor cell invasion assays: Comparison of human amnion vs. reconstituted basement membrane. Invasion Metas 9:278-297, 1989.

36. Seftor REB, Seftor EA, Cress AE and Hendrix MJC. Identification of externally exposed plasma

membrane proteins associated with tumor cells of high and low metastatic potential. Pig Cell Res 3:44-48, 1990.

37. Meade-Tollin LC, Pipes BL, Anderson SJ, Seftor EA and Hendrix MJC. A comparison of levels of

intrinsic single strand breaks\alkali labile sites associated with human melanoma cell invasion. Cancer Letters 53:45-54, 1990.

38. Persky B and Hendrix MJC. Artificial matrix barriers: A diffusion study utilizing dextrans and

microspheres. Anat Rec 228:15-22, 1990. 39. Bevacqua SJ, Welch DR, Diez de Pinos SW, Shapiro SA, Johnston MG, Witte MH, Leong SLP,

Dorrance TL, Leibovitz A and Hendrix MJC. Quantitation of human melanoma, carcinoma and sarcoma tumor cell adhesion to lymphatic endothelium. Lymphology 23:4-14, 1990.

40. Hendrix MJC, Wood WR, Seftor EA, Lotan D, Nakajima M, Misiorowski RL, Seftor REB, Stetler-

Stevenson WG, Bevacqua SJ, Liotta LA, Sobel ME, Raz A and Lotan R. Retinoic acid inhibits human melanoma tumor cell invasion through a reconstituted basement membrane and its relation to decreased in the expression of proteolytic enzymes and motility factor receptor. Cancer Res 50:4121-4130, 1990.

41. Wood WR, Seftor EA, Lotan D, Nakajima M, Seftor REB, Misiorowski RL, Lotan R and Hendrix

MJC. Retinoic acid inhibits human melanoma tumor cell invasion. Anticancer Res 10:423-432, 1990.

42. Seftor EA, Seftor REB and Hendrix MJC. Selection of invasive and metastatic subpopulations

from a heterogeneous human melanoma cell line. Biotechniques 9(3):324-331, 1990. 43. Chu Y-W, Duffy JJ, Seftor REB, Nagle RB and Hendrix MJC. Transfection of a deleted CK18

cDNA into a highly metastatic melanoma cell line decreases the invasive potential. J Clin Biotech 3:27-33, 1991.

44. Welch DR, Bisi JE, Miller BE, Conaway D, Seftor EA, Yohem KH, Gilmore LB, Seftor REB,

Nakajima M and Hendrix MJC. Characterization of a highly invasive and spontaneously metastatic human malignant melanoma cell line. Int J Cancer 47:227-237, 1991.

45. Hendrix MJC, Seftor EA, Eckes MD, Winters AL, Leong SPL and Scuderi P. Effects of interferon-

gamma on the expression of HLA-DR by human melanoma cells of varying metastatic potential. Pigment Cell Res 3:162-167, 1991.

46. Seftor REB, Seftor EA, Grimes WJ, Liotta LA, Settler-Stevenson WG, Welch DR and Hendrix

MJC. Human melanoma cell invasion is inhibited in vitro by swainsonine and deoxymannojirimycin with a concomitant decrease in collagenase IV expression. Melanoma Res 1(1):43-54, 1991.

Mary J.C. Hendrix

47. Sundareshan P, Davis JR, Korc M and Hendrix MJC. The effects of EGF on growth response, morphology and invasive potential of a human endometrial carcinoma cell line. Cancer Commun 3:149-158, 1991.

48. Matsushita Y, Nakamori S, Seftor EA, Hendrix MJC and Irimura T. Human colon carcinoma cells

with increased invasive capacity obtained by selection for sialyl-dimeric Lex antigen. Exp Cell Res 196:20-25, 1991.

49. Matrisian LM, McDonnell S, Miller DB, Navre M, Seftor EA and Hendrix MJC. The role of the

matrix metalloproteinase stromelysin in the progression of squamous cell carcinomas. Am J Med Sci 302:157-162, 1991.

50. Sundareshan P and Hendrix MJC. Growth, morphological and invasive characteristics of two in

vitro passages of a human endometrial adenocarcinoma cell line. In Vitro Cell Develop Biol 28:544-552, 1992.

51. Yohem KH, Clothier JL, Montague SL, Geary RJ, Winters AL, Hendrix MJC and Welch DR.

Inhibition of tumor cell invasion and metastasis by pretreatment with calcium channel antagonists. Pigment Cell Res 4:31-39, 1992.

52. Garewal H, Leibovitz A, Sampliner R, Ramsey L, Sloan D and Hendrix MJC. Tissue culture of

epithelial cells from esophageal specialized columnar epithelium (Barrett’s). Dig Dis Sci 37:532-536, 1992.

53. Hendrix MJC, Seftor EA, Grogan TM, Seftor REB, Hersh E, Boyse EA, Liotta LA, Stetler-

Stevenson WG and Ray CG. Invasion of human lymphoblastoid cell lines is correlated with the expression of type IV collagenase and pathogenesis in SCID mice. Molecular Cell Probes 6:57-65, 1992.

54. Hendrix MJC, Seftor EA, Chu Y-W, Seftor REB, Nagle RB, McDaniel KM, Leong SPL, Yohem KH,

Leibovitz AM, Meyskens F.L Jr., Conaway DH, Welch DR, Liotta LA and Stetler-Stevenson WG. Coexpression of vimentin and cytokeratins by human melanoma tumor cells: Correlation with invasive and metastatic potential. J Natl Cancer Inst 84:165-174, 1992. (*Journal Highlight)

55. Seftor REB, Seftor EA, Gehlsen KR, Stetler-Stevenson WG, Brown PD, Ruoslahti E and Hendrix

MJC. Role of the v3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 89:1557-1561, 1992.

56. Buckley AR, Montgomery DW, Hendrix MJC, Zukoski CF and Putnam CW. Identification of

prolactin receptors in hepatic nuclei. Arch Biochem Biophys 296:198-206, 1992. 57. Gehlsen KR, Hadley ME, Levine N, Ray CG and Hendrix MJC. Effects of melanotropins on tumor

cell invasion and metastasis. Pigment Cell Res 5:219-233, 1992. 58. Shipp NG, Dorr RT, Alberts DS, Dawson BV and Hendrix MJC. Characterization of experimental

mitoxantrone cardiotoxicity and its partial inhibition by ICRF-187 in cultured neonatal rat heart cells. Cancer Res 53:550-556, 1993.

59. Repesh LA, Drake SR, Warner MC, Downing SW, Seftor EA, Hendrix MJC and McCarthy JB.

Adriamycin-induced inhibition of melanoma cell invasion is correlated with decreases in tumor cell motility and increases in focal contact formation. J Clin Exp Metas 11:91-102, 1993.

Mary J.C. Hendrix

60. Chu Y-W, Runyan RB, Oshima RG and Hendrix MJC. Expression of complete keratin filaments in mouse L cells augments cell migration and invasion. Proc Natl Acad Sci USA 90:4261-4265, 1993.

61. Seftor REB, Seftor EA, Stetler-Stevenson WG and Hendrix MJC. The 72 kDa type IV collagenase

is modulated via differential expression of v3 and 5 1 integrins during human melanoma cell invasion. Cancer Res 53:3411-3415, 1993.

62. Bull DA, Seftor EA, Hendrix MJC, Larson DF, Hunter GC and Putnam CW. Putative vascular

endothelial cell chemotactic factors: Comparison in a standardized migration assay. J Surg Res 55:473-479, 1993.

63. Zou Z, Anisowicz A, Hendrix MJC, Neveu M, Thor A, Radifi K, Seftor EA, Stenman G and Sager

R. Identification of Maspin, a novel serpin with tumor suppressing activity in human mammary epithelial cells. Science 263:526-529, 1994.

64. Tsang TC, Chu Y-W, Powell M, Kittelson J, Meade-Tollin L, Hendrix MJC and Bowden GT. V-jun

oncogene suppresses both phorbol ester induced cell invasion and stromelysin gene expression in a mouse papilloma cell line. Cancer Res 54:882-886, 1994.

65. Ray RB, Steele R, Seftor E and Hendrix MJC. Human breast carcinoma cells transfected with the

gene encoding c-myc promoter binding protein (MBP-1) inhibits tumors in nude mice. Cancer Res 55:3747-3751, 1995.

66. Chu Y-W, Seftor EA, Romer LH and Hendrix MJC. Experimental coexpression of vimentin and

keratin IFs in melanoma cells augments motility. Am J Pathol 148:63-69, 1996. 67. Martinez-Azaguilan R, Seftor EA, Seftor REB, Chu Y-W, Gillies RJ and Hendrix MJC. Acidic pH

enhances the invasive behavior of human melanoma cells. Clin Exp Metas 14:176-186, 1996. 68. Frye CA, Yocum DE, Tuan R, Seftor EA, Seftor REB, Moore TL and Hendrix MJC. An in vitro

model for studying mechanisms underlying synoviocyte-mediated cartilage destruction in rheumatoid arthritis. Pathology Oncology Research 2:157-167, 1996.

69. Ruiz ME, Freeman J, Bouhasin JD, Knutsen AP and Hendrix MJC. Arrest of in vitro T cell

differentiation of normal bone marrow derived CD34+ stem cells cocultured with thymic epithelial fragments from children with AIDS. Stem Cells 14:533-547, 1996.

70. Gatenby RA, Seftor EA and Hendrix MJC. Fibroblast enhancement of tumor invasion in a tumor-

host interface recapitulated in vitro. Pathology Oncology Research 2:151-157, 1996. 71. Sheng S, Carey J, Hendrix MJC, Seftor EA, Dias L and Sager R. Maspin acts at the cell

membrane to inhibit invasion and motility of mammary and prostate cancer cells. PNAS 93:11669-11674, 1996.

72. Stuiver I, Hendrix MJC, Shimizu Y and Shimizu N. The phorbol ester TPA regulates collagen

gene expression at the transcriptional level. Cell Structure and Function 21:259-269, 1996. 73. Hendrix MJC, Seftor EA, Chu Y-W, Trevor KT and Seftor REB. Role of intermediate filaments in

migration, invasion, and metastasis. Cancer and Metastasis Reviews 15:507-525, 1996. 74. Hendrix MJC. Overview of intermediate filaments. Cancer Metas Reviews 15:413-416, 1996.

Mary J.C. Hendrix

75. Chu Y-W, Yang P-C, Yang S-C, Shyu Y-C, Hendrix MJC, Wu R and Wu C-W. Selection of

invasive and metastatic subpopulations from a human lung adenocarcinoma cell line. Amer J Resp Cell and Mol Biol 17(3):353-360, 1997.

76. Hendrix MJC, Seftor EA, Seftor REB and Trevor KT. Experimental coexpression of vimentin and

keratin intermediate filaments in human breast cancer cells is associated with increased motility and phenotypic interconversion. Amer J Pathol 150:483-496, 1997.

77. Hendrix MJC, Muschel RJ and Padarathsingh M. Recent advances in breast cancer research:

From genes to management. Amer J Pathol 151:361-367, 1997. 78. Luo J, Sharma N, Seftor EA, De Larco J, Heidger PM, Hendrix MJC and Lubaroff DM.

Heterogeneous expression of invasive and metastatic properties in a prostate model. Pathology Oncology Research 3:264-271, 1997.

79. Khalkhali-Ellis Z, Seftor EA, Nieva DRC, Seftor REB, Samaha HAM, Bultman L, De Larco JE, Ince

A, Moore TL and Hendrix MJC. Induction of erosive and degrading phenotype in normal synoviocytes exposed to synovial fluid from JRA patients: Role of mononuclear cell population. J Rheum 24:2451-2460, 1997.

80. Hendrix MJC, Seftor EA, Seftor REB, Gardner LM, Boldt HC, Meyer M, Pe’er J and Folberg R.

Biological determinants of uveal melanoma metastatic phenotype: Role of intermediate filaments as predictive markers. Lab Invest 78:153-163, 1998. (*Cover Illustration)

81. Seftor REB, Seftor EA, De Larco JE, Kleiner DE, Leferson J, Stetler-Stevenson G, McNamara TF,

Golub LM and Hendrix MJC. Chemically modified tetracyclines inhibit human melanoma cell invasion and metastasis. Clin Exp Metas 16(3):217-225, 1998.

82. Hendrix MJC, Seftor EA, Seftor REB, Kirschmann DA, Gardner LM, Boldt HC, Meyer M, Pe’er J

and Folberg R. Regulation of uveal melanoma interconverted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Path 152:855-863, 1998. (*Cover Illustration)

83. Khalkhali-Ellis Z, Roodman S, Knutsen A, Mueller K, Chauhan B, Moore T and Hendrix MJC.

Expression of macrophage markers by a population of T cells obtained from the synovial fluid of a subgroup of JRA patients. J Rheum, 25:352-360, 1998.

84. Aupperle K, Boyle DL, Hendrix MJC, Seftor EA, Zvaifler NJ, Barbosa M and Firestein GS.

Regulation of synoviocyte proliferation, apoptosis and invasiveness by the p53 tumor suppressor gene. Amer J Pathol 152:1091-1098, 1998.

85. Grover-McKay M, Walsh SA, Seftor EA, Thomas PA and Hendrix MJC. Role for glucose

transporter 1 protein in human breast cancer. Pathology Oncology Research 4(2):115-120, 1998. 86. Seftor EA, Seftor REB, Nieva DRC, and Hendrix MJC. Application of chemically modified

tetracyclines (CMTs) in experimental models of cancer and arthritis. Adv Dental Res 12:103-110, 1998.

87. D’Alessandro MP, D’Alessandro DM, Hendrix MJC and Bakalar RS. The Virtual Naval Hospital:

A digital library for Naval Primary Care Providers and Patients. Military Medicine 163, 11:775, 1998.

Mary J.C. Hendrix

88. Seftor REB, Seftor EA, Sheng S, Pemberton P, Sager R and Hendrix MJC. Molecular regulation of maspin’s inhibitory effects on human breast carcinoma invasive potential. Cancer Res 58:5681-5685, 1998.

89. Khalkhali-Ellis Z, Moore TL and Hendrix MJC. Reduced levels of testosterone and

dehyroepiandrosterone sulphate in the synovial fluid of juvenile rheumatoid arthritis patients correlates with disease progression. Clinical and Experimental Rheumatology 16:753-756, 1998.

90. Martinez-Zaguilan R, Martinez GM, Gomez A, Hendrix MJC and Gillies RJ. Distinct regulation of

pHin and [Ca2+]in in human melanoma cells with different metastatic potential. J Cell Physiol 176:196-205, 1998.

91. Gutmann DH, Sherman L, Seftor EA, Haipek C, Lu KH and Hendrix MJC. Increased expression

of the NF2 tumor suppressor gene product, merlin, impairs cell motility, adhesion and spreading. Human Molecular Genetics 8(2):267-275, 1999.

92. Kirschmann DA, Seftor EA, Nieva DRC, Mariano EA and Hendrix MJC. Differentially expressed

genes associated with the metastatic phenotype in breast cancer. Breast Cancer Res Treat 55:127-136, 1999.

93. Hendrix MJC. A modern anatomist at the helm of FASEB [editorial]. Anatom Record 257:117-

118, 1999. 94. Sharma N, Luo J, Kirschmann DA, O’Malley Y, Robbins MEC, Akporiaye ET, Lubaroff DM,

Heidger PM and Hendrix MJC. A novel immunological model for the study of prostate cancer. Cancer Research 59:2271-2287, 1999.

95. D’Alessandro DM, D’Alessandro MP, Hendrix MJC and Bakalar RS. Information needs of naval

primary care providers and patients at sea. Military Medicine 164. 2:127, 1999. 96. Luo J, Lubaroff DM and Hendrix MJC. Suppression of prostate cancer invasive phenotype by E-

cadherin transfection. Cancer Research 59:3552-3556, 1999. 97. Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LMG, Pe’er J, Trent JM, Meltzer PS and

Hendrix MJC. Vascular channel formation by human melanoma cells in vivo and in vitro: Vasculogenic mimicry. Am J Path 155(3):739-752, 1999. (Journal Commentary)

98. Lam EWN, Zwacka R, Seftor EA, Nieva DRC, Davidson BL, Engelhardt JF, Hendrix MJC and

Oberley LW. The effects of antioxidant enzyme expression on the invasive phenotype of hamster cheek pouch carcinoma cells. Free Radic Biol Med 27:572-579, 1999.

99. Thomas PA, Kirschmann DA, Cerhan JR, Folberg R, Seftor EA, Sellars TA and Hendrix MJC.

Association between keratin and vimentin expression, malignant phenotype and survival in postmenopausal breast cancer patients. Clin Cancer Res, 5:2698-2703, 1999.

100. Khalkhali-Ellis Z, Bulla GA, Schlesinger LS, Kirschmann DA, Moore TL and Hendrix MJC. C1q

containing immune complexes purified from sera of juvenile rheumatoid arthritis patients mediate IL-8 production by human synoviocytes. J Immunology, 163:4612-4620, 1999.

101. Hendrix MJC, Seftor EA and Kirschmann DA. New molecular markers to study breast cancer

progression. Cancer Research Alert, 7(1):75-78, 1999.

Mary J.C. Hendrix

102. Seftor REB, Seftor EA and Hendrix MJC. Molecular role(s) for integrins in human melanoma invasion. Cancer Metas Reviews, 18:359-375, 1999.

103. Cohen MC, Padarathsingh M and Hendrix MJC. Meeting Report: Experimental Models of

Prostate Cancer Research, Am J Path, 156(1):355-358, 2000. 104. Khalkhali-Ellis Z, Moore TL and Hendrix MJC. Viewpoint: Could hormones make a difference in

the treatment of juvenile rheumatoid arthritis. BioDrug 13(2):77-86, 2000. 105. Folberg R, Hendrix MJC and Maniotis AJ. Vasculogenic mimicry and tumor angiogenesis. Am J

Path 156(2):361-381, 2000. 106. Domann FE, Rice JC, Hendrix MJC and Futscher BW. Epigenetic silencing of maspin gene

expression in human breast cancers, Int J Cancer 85:805-810, 2000. 107. Khalkhali-Ellis Z, Seftor EA, Nieva DRC, Handa RJ, Price RH, Kirschmann DA, Baragi VM,

Sharma RV, Bhalla RC, Moore TL and Hendrix MJC. Sex hormone regulation of synoviocyte function in vitro: Implications in rheumatoid arthritis. J Rheumatol 27:1622-1631, 2000.

108. Anguelo Z, Seftor REB, Seftor EA, Sood AK and Hendrix MJC. Cytoskeleton proteins as markers

for an enhanced metastatic potential: New possibilities in cancer management. Currents 1:1-3, 2000.

109. Kirschmann DA, Lininger RA, Gardner LM, Seftor EA, Odero VA, Ainsztein AM, Earnshaw WC,

Wallrath LL and Hendrix MJC. Down regulation of HP1Hsα expression is associated with the metastatic phenotype in breast cancer. Cancer Research 60:3359-3363, 2000.

110. Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z,

Ben-Dor A, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Dietrick K, Alberts D, Sondak V, Hayward N and Trent J. Molecular classification of cutaneous malignant melanoma by gene expression: Shifting from a continuous spectrum to distinct biologic entities. Nature 406:536-540, 2000.

111. Hendrix MJC. De-mystifying the mechanism(s) of maspin. Nature Medicine 6:374-376, 2000. 112. Hendrix MJC, Seftor EA, Kirschmann DA and Seftor REB. Molecular biology of breast cancer

metastasis: Molecular expression of vascular markers by aggressive breast cancer cells. Breast Cancer Research 2:417-422, 2000.

113. McEarchern JA, Kobie JJ, Mack V, Wu RS, Meade-Tollin L, Arteaga CL, Dumont N, Besselsen D,

Seftor E, Hendrix MJC, Katsanis E and Akporiaye ET. Invasion and metastasis of a mammary tumor involves TGF-α signaling. Int J Cancer 91:76-82, 2001.

114. Zheng W, Seftor EA, Meininger CJ, Hendrix MJC and Tomanek RJ. Mechanisms of coronary

angiogenesis in response to stretch: Role of VEGF and TGF. Amer J Physiol 280:H909-H917, 2001.

115. Sood AK, Seftor EA, Fletcher MS, Gardner LMG, Heidger PM, Buller RE, Seftor REB and Hendrix

MJC. Molecular determinants of ovarian cancer plasticity. Amer J Pathol 158(4):1279-1288, 2001.

Mary J.C. Hendrix

116. Sood AK, Holmes R, Hendrix MJC and Buller RE. Application of the National Cancer Institute criteria for determination of microsatellite instability in ovarian cancer. Cancer Res 61:4371-4374, 2001.

117. Hess AR, Seftor EA, Gardner LMG, Carles-Kinch K, Schneider GB, Seftor REB, Kinch MS and

Hendrix MJC. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: Role of epithelial cell kinase. Cancer Res 61:3250-3255, 2001.

118. Hendrix MJC, Seftor EA, Meltzer PM , Gardner LMG , Hess AR, Kirschmann DA, Schatteman GC

and Seftor REB. Expression and functional significance of VE-cadherin in aggressive human melanoma cells: Role in vasculogenic mimicry. PNAS, USA, 98:8018-8023, 2001.

119. Seftor REB, Seftor EA, Gardner LMG, Bilban M, Koshikawa N, Meltzer PS, Stetler-Stevenson

WG, Quaranta V and Hendrix MJC. Cooperative interactions of Laminin 2, MMP-2 and MT1-MMP are required for mimicry of embryonic vasculogenesis by aggressive melanoma. Cancer Res 61:6322-6327, 2001. (Cover Illustration)

120. Hendrix MJC and Campbell P. Communicating Science: From the laboratory bench to the

breakfast table. The Anatomical Record (New Anat.) 265(4):165-167, 2001. 121. Dokras A, Gardner LMG, Seftor EA and Hendrix MJC. Regulation of human cytotrophoblast

morphogenesis by hepatocyte growth factor/scatter factor. Biol Reprod 65:1278-1288, 2001. 122. Dokras A, Gardner LMG, Kirschmann DA, Seftor EA and Hendrix MJC. The tumor suppressor

gene maspin is differentially regulated in cytotrophoblasts during human placental development. Placenta 23(4):274-280, 2001.

123. Hendrix MJC, Seftor REB, Seftor EA, Gruman LM, Lee LM, Nickoloff B, Miele L, Sheriff DD and

Schatteman GC. Transendothelial function of human metastatic melanoma cells: Role of the microenvironment in cell-fate determination. Cancer Res 62:665-668, 2002. (Cover Illustration)

124. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, Hendrix MJC and Sood

AK. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 8, 3193-3197, 2002.

125. Sharma N, Seftor REB, Seftor EA, Gardner LM, Heidger PM, Cohen MB, Lubaroff DM and

Hendrix MJC. Prostatic vasculogenic mimicry involves co-operative interactions of distinct phenotypic subpopulations. The Prostate 50:189-201, 2002.

126. Sood AK, Fletcher MS and Hendrix MJC. The embryonic properties of aggressive human tumor

cells. J Soc Gyn Invest 9(1):1-9, 2002. 127. Seftor EA, Meltzer PS, Kirschmann DA, Pe’er J, Maniotis AJ, Trent JM, Folberg R and Hendrix

MJC. Molecular determinants of human uveal melanoma invasion and metastasis. Clin & Exp Metastasis 19:233-246, 2002.

128. Korn D, Rich RR, Garrison HH, Golub SH, Hendrix MJC, Heinig SJ, Masters BS and Turman RJ.

The NIH budget in the “Postdoubling” era. Science 296:1401-1402, 2002. 129. Odero-Marah VA, Khalkhali-Ellis Z, Schneider GB, Seftor EA, Seftor REB, Koland JG and Hendrix

MJC. Tyrosine phosphorylation of the serpin maspin in normal mammary epithelia and breast cancer cell lines. Biochem Biophys Res Comm 295:800-805, 2002.

Mary J.C. Hendrix

130. Kirschmann DA, Seftor EA, Fong SF, Nieva DRC, Sullivan CM, Edwards EM, Sommer P, Csiszar

K and Hendrix MJC. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 62:4478-4483, 2002.

131. Seftor EA, Meltzer PS, Schatteman GC, Gruman LMG, Hess AR, Kirschmann DA, Seftor REB

and Hendrix MJC. Expression of multiple molecular phenotypes by aggressive melanoma tumor cells: Role in vasculogenic mimicry. Crit Rev Oncol Hematol 44:17-27, 2002.

132. Hendrix MJC, Seftor EA, Meltzer PS, Hess AR, Gruman LM, Nickoloff BJ, Miele L, Sheriff DD,

Schatteman GC, Bourdon MA and Seftor REB. The plasticity of aggressive melanoma tumor cells: Recapitulation of an embryonic stem cell program. Recent Adv Res Updates 3:192-200, 2002.

133. Sood AK, Fletcher MS, Gruman LM, Coffin JM, Jabbari S, Khalkhali-Ellis Z, Arbour N, Seftor EA

and Hendrix MJC. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 8:2924-2932, 2002.

134. Seftor REB, Seftor EA, Kirschmann DA and Hendrix MJC. Targeting the tumor microenvironment

with chemically modified tetracyclines: Inhibition of Laminin 5 2 chain promigratory fragments and vasculogenic mimicry. Molecular Cancer Therapeutics 1:1173-1179, 2002.

135. Herlyn M, Padarathsingh M, Chin L, Hendrix M, Becker D, Nelson M, DeClerk Y, McCarthy J and

Mohla S. New approaches to the biology of melanoma: A workshop of the National Institutes of Health Pathology B Study Section. Am J Path 161(5): 1949-1957, 2002.

136. Schneider GB, Kurago Z, Zaharias R, Gruman LM, Schaller MD and Hendrix MJC. Elevated focal

adhesion kinase expression facilitates oral tumor cell invasion. Cancer 95(12): 2508-2515, 2002. 137. Sood AK, Buller RE, Coffin J, Jabbari S, Hendrix, MJC and Klingelhutz A. p53 null mutations are

associated with a telomerase negative phenotype in ovarian carcinoma. Cancer Biol Therapy 1(5): 511-517, 2002.

138. Sood AK, Fletcher MS, Zahn CM, Gruman LM, Coffin JM, Seftor EA and Hendrix MJC. The

clinical significance of tumor cell-lined vasculature in ovarian carcinoma: Implications for anti-vasculogenic therapy. Cancer Biol Therapy 1: 661-664, 2002. (Cover Illustration)

139. Hendrix MJC. The potential clinical use of exploiting metastasis suppressor genes in regulating

prostatic cancer. Journal of Urology 169, 2003. 140. Khalkhali-Ellis Z and Hendrix MJC. Nitric oxide regulation of maspin expression in normal

mammary epithelial and breast cancer cells. Am J Path, 162(5): 1411-1417, 2003. 141. Walker-Daniels J, Hess AR, Hendrix MJC and Kinch MS. Differential regulation of EphA2 in

normal and malignant cells. Am J Path, 162(4): 1037-1042, 2003. 142. Sood AK and Hendrix MJC. The complexity of tumor vascularity. Cancer Biology Ther, 2(3):257-

258, 2003. (Cover Illustration) 143. Hendrix MJC, Seftor EA, Hess AR and Seftor RE. Molecular plasticity of human melanoma cells.

Oncogene Reviews, 22(20):3070-3075, 2003.

Mary J.C. Hendrix

144. Seftor REB, Seftor EA, Hess AR and Hendrix MJC. The role of the vasculogenic phenotype and its associated extracellular matrix in tumor progression: Implications for immune surveillance. Clin Applied Immunol Reviews, 3:263-276, 2003.

145. Hendrix MJC, Seftor EA, Hess AR and Seftor RE. Vasculogenic mimicry and tumour-cell plasticity:

lessons from melanoma. Nature Rev Cancer, 3(6):411-421, 2003. 146. Hess AR, Seftor EA, Seftor RE and Hendrix MJC. Phosphoinositide 3-kinase regulates membrane

Type 1-matrix metalloproteinase (MMP) and MMP-2 activity during melanoma cell vasculogenic mimicry. Cancer Res, 63(16):4757-4762, 2003.

147. Ruf W, Seftor EA, Petrovan RJ, Weiss RM, Gruman LM, Margaryan NV, Seftor RE, Miyagi Y and

Hendrix MJC. Differential role of tissue factor pathway inhibitors 1 and 2 (TFPI-1 and 2) in melanoma vasculogenic mimicry. Cancer Res, 63(17):5381-5389, 2003.

148. Odero-Marah V, Khalkhali-Ellis Z, Seftor EA, Chunthapong J, Seftor RE and Hendrix MJC. Maspin

regulates different signaling pathways for motility and adhesion in aggressive breast cancer cells. Cancer Biol Ther, 2(4):398-403, 2003.

149. Khalkhali-Ellis Z, Christian AL, Kirschmann DA, Edwards EM, Rezaie-Thompson M, Vasef MA,

Gruman LM, Seftor RE, Norwood LE and Hendrix MJC. Regulating the tumor suppressor gene maspin in breast cancer cells: a potential mechanism for the anticancer properties of tamoxifen. Clin Cancer Res, 10(2):449-454, 2004. (Cover Highlight)

150. DeClerck YA, Stack MS, Zutter MM, Mercurio AM, Raz A, Matrisian L, Sloane BF, Muschel RJ,

Coussens L, Noel A, Hendrix MJC and Padarathsingh M. Proteases, Extracellular Matrix and Cancer: A workshop of the PathB study section. Am J Path, 164(4): 1131-1139, 2004.

151. Chunthapong J, Seftor EA, Khalkhali-Ellis Z, Seftor REB, Amir S, Lubaroff DM, Heidger PM Jr.

and Hendrix MJC. Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem, 91(4):649-661, 2004.

152. van der Schaft DWJ, Seftor RE, Seftor EA, Hess AR, Gruman LM, Kirschmann DA, Yokoyama Y,

Griffioen AW and Hendrix MJC. Effects of angiogenesis inhibitors on vascular network formation by human endothelial and melanoma cells. J Natl Cancer Inst., 96(19):1473-1477, 2004.

153. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, Gershenson DM and Hendrix MJC. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Amer J Obstet Gynecol, 190(4):899-909, 2004.

154. Rojas JD, Sennoune SR, Martinez GM, Bakunts K, Meininger CJ, Wu G, Wesson DE, Seftor EA, Hendrix MJC and Martinez-Zaguilan R. Plasmalemmal vacuolar H+-ATPase is decreased in microvascular endothelial cells from a diabetic model. J Cell Physiol, 201(2):190-200, 2004.

155. Futscher BW, O’Meara MM, Kim CJ, Rennels MA, Lu D, Gruman LM, Seftor RE, Hendrix MJC and Domann FE. Aberrant methylation of the maspin promoter is an early event in human breast cancer. Neoplasia, July-Aug; 6(4):380-389, 2004.

156. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJC, Seftor RE, Seftor EA, Margaryan NV, Pollock PM, Curtis A, Trent JM, Bennett F, Miele L and Nickoloff BJ. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther, 3(8):895-902, 2004.

Mary J.C. Hendrix

157. Sood AK, Coffin JE, Schneider GB, Fletcher MS, DeYoung BR, Gruman LM, Gershenson DM, Schaller MD and Hendrix MJC. Biological significance of FAK in ovarian cancer: role in migration and invasion. Am J Path, 165(4):1087-1095, 2004.

158. Norwood LE, Grade SK, Cryderman DE, Hines KA, Furiasse N, Toro R, Li Y, Dhasarathy A, Kladde MP, Hendrix MJC, Kirschmann DA and Wallrath LL. Conserved properties of HP1Hsα. Gene 336(1):37-46, 2004.

159. Amir S, Margaryan NV, Odero-Marah V, Khalkhali-Ellis Z and Hendrix MJC. Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells. Cancer Biology and Therapy, 4(4):400-406, 2005. (*Journal Highlight)

160. Bailey CM, Khalkhali-Ellis Z, Kondo S, Margaryan N, Amir S, Schutte B and Hendrix MJC. Maspin binds directly to interferon regulatory factor 6: Identification of a novel serpin partnership. J Biol Chem, 280:34210-34217, 2005.

161. Payne SL, Fogelgren B, Hess AR, Wiley EL, Seftor EA, Fong SFT, Csiszar K, Hendrix MJC and Kirschmann, DA. Lysyl oxidase regulates breast cancer cell migration and adhesion through a hydrogen peroxide-mediated mechanism. Cancer Research, 65:11429-11436, 2005.

162. Lee LMJ, Seftor EA, Bonde G, Cornell RA and Hendrix MJC. The fate of human malignant melanoma cells transplanted into zebrafish embryos: assessment of migration and cell division in the absence of tumor formation. Developmental Dynamics, 233:1560-1570, 2005.

163. Nickoloff BJ, Hendrix MJC, Pollock PM, Trent JM, Miele L and Qin JZ. Notch and NOXA-related pathways in melanoma cells. Journal of Investigative Dermatology, 10:95-104, 2005.

164. Qin JZ, Ziffra J, Stennett L, Bodner B, Bonish BK, Chaturvedi V, Bennett F, Pollock PM, Trent JM, Hendrix MJC, Rizzo P, Miele L and Nickoloff BJ. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Research, 65(14): 6282-6293, 2005.

165. Seftor EA, Brown KM, Chin L, Kirschmann DA, Wheaton W, Protopopov A, Feng B, Balagurunathan Y, Trent JM, Nickoloff BJ, Seftor REB and Hendrix MJC. Epigenetic transdifferentiation of normal melanocytes by a metastatic melanoma microenvironment. Cancer Research, 65(22) 10164-10169, 2005. (*Journal Highlight)

166. Hess AR, Postovit LM, Margaryan NV, Seftor EA, Schneider GB, Seftor REB, Nickoloff BJ and Hendrix MJC. Focal adhesion kinase promotes the aggressive melanoma phenotype. Cancer Research, 65(21):9851-9860, 2005.

167. van der Schaft DWJ, Hillen F, Pauwels P, Kirschmann DA, Castermans K, oude Egbrink MGA, Tran MGB, Sciot R, Hauben E, Hogendoorn PCW, Delattre O, Maxwell PH, Hendrix MJC and Griffioen AW. Tumor cell plasticity in Ewing sarcoma: an alternative circulatory system stimulated by hypoxia. Cancer Research, 65:11520-11528, 2005.

168. Kulesa PM, Kasemeier JC, Teddy JM, Margaryan NV, Seftor EA, Seftor REB and Hendrix MJC. Reprogramming metastatic melanoma cells to assume a neural crest cell-like phenotype in an embryonic microenvironment. PNAS, 103(10):3752-3757, 2006.

169. Payne SL, Hendrix MJC and Kirschmann DA. Lysyl oxidase regulates actin filament formation through the p130Cas/Crk/DOCK180 signaling complex. J Cell Biochem, 98:827-837, 2006.

Mary J.C. Hendrix

170. Hess AR, Seftor EA, Gruman LM, Kinch MS, Seftor REB and Hendrix MJC. VE-cadherin regulates EphA2 in aggressive melanoma cells through a novel signaling pathway: implications for vasculogenic mimicry. Cancer Biol Therapy, 5(2):228-233, 2006. (Cover Illustration)

171. Topczewska JM, Postovit LM, Margaryan NV, Sam A, Hess AR, Wheaton WV, Nickoloff BJ, Topczewski J and Hendrix MJC. Embryonic and tumorigenic pathways converge via Nodal signaling: Role in melanoma aggressiveness. Nature Medicine, 12:925-932, 2006. (Journal Commentary)

172. Seftor EA, Meltzer PS, Kirschmann DA, Margaryan NV, Seftor REB and Hendrix MJC. The epigenetic reprogramming of poorly aggressive melanoma by a metastatic melanoma microenvironment. J Cell Molec Med, 10:174-196, 2006.

173. Rojas JD, Sennoune SR, Maiti D, Bakunts K, Reuveni M, Sanka SC, Martinez GM, Seftor EA, Meininger CJ, Wu G, Wesson DE, Hendrix MJC and Martinez-Zaguilan R. Vacuolar Type H+-ATPases at the plasma membrane regulate pH and cell migration in microvascular endothelial cells. J Cell Physiol: Heart Circ Physiol 291(3):H1 147-157, 2006.

174. Postovit LM, Seftor EA, Seftor REB and Hendrix MJC. Influence of the microenvironment on melanoma cell-fate determination and phenotype. Cancer Research, 66:7833-7836, 2006.

175. Postovit LM, Seftor EA, Seftor REB and Hendrix MJC. A Three-dimensional model to study the epigenetic effects induced by the microenvironment of human embryonic stem cells. Stem Cells, 24:501-505, 2006.

176. Norwood LE, Moss TJ, Margaryan NV, Cook SL, Wright L, Seftor EA, Hendrix MJC, Kirschmann DA and Wallrath LL. A requirement for dimerization of HP1Hsalpha in suppression of breast cancer invasion. J Biol Chem, 281:18668-18676, 2006.

177. Bailey CM, Khalkhali-Ellis Z, Seftor EA and Hendrix MJC. The biological functions of maspin. J Cell Physiol, 209:617- 624, 2006.

178. Postovit LM, Costa FF, Bischof JM, Seftor EA, Wen B, Seftor REB, Feinberg AP, Soares MB and Hendrix MJC. The commonality of plasticity underlying multipotent tumor cells and embryonic stem cells. J Cell Biochem, 101:908-917, 2007.

179. Dome B, Hendrix MJC, Paku S, Tovari J and Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol, 170(1):1-15, 2007.

180. Hendrix MJC, Seftor EA, Seftor REB, Kasemeier-Kulesa J, Kulesa P and Postovit LM. Reprogramming metastatic tumour cells with embryonic microenvironments. Nature Rev Cancer, 7:246-255, 2007.

181. Postovit LM, Seftor EA, Seftor REB and Hendrix MJC. Targeting Nodal in malignant melanoma cells. Expert Opin Therapeut Targets, 11:497-505, 2007.

182. Khalkhali-Ellis Z and Hendrix MJC. Elucidating the function of secreted maspin. Cancer Res, 67(8):3535-3539, 2007.

183. Payne SL, Hendrix MJC and Kirschmann DA. Paradoxical roles for lysyl oxidases in cancer - a prospect. J Cell Biochem, 101:1338-1354, 2007.

Mary J.C. Hendrix

184. Li LZ, Zhou R, Zhong T, Moon L, Kim EJ, Qiao H, Pickup S, Hendrix MJC, Leeper D, Chance B and Glickson JD. Predicting melanoma metastatic potential by optical and magnetic resonance imaging. Adv Exp Med Biol. 599:67-78, 2007.

185. Abbott DE, Postovit LM, Seftor EA, Margaryan NV, Seftor RE and Hendrix MJC. Exploiting the convergence of embryonic and tumorigenic signaling pathways to develop new therapeutic targets. Stem Cell Rev 3(1):68-78, 2007.

186. Hess AR, Margaryan NV, Seftor EA and Hendrix MJC. Deciphering the signaling events that promote melanoma tumor cell vasculogenic mimicry and their link to embryonic vasculogenesis: Role of the Eph receptors. Developmental Dynamics Reviews, 236(12):3283-3296, 2007.

187. Postovit LM, Abbott DE, Payne SL, Wheaton WW, Margaryan NV, Sullivan R, Jansen MK, Csiszar

K, Hendrix MJC and Kirschmann DA. Hypoxia/reoxygenation: A dynamic regulator of lysyl oxidase-facilitated breast cancer migration. J Cell Biochem, 103:1369:1378, 2008.

188. Postovit LM, Margaryan NV, Seftor EA, Kirschmann DA, Lipavsky A, Wheaton WW, Abbott DE, Seftor REB and Hendrix MJC. Human embryonic stem cell microenvironment suppresses the tumorigenic phenotype of aggressive cancer cells. PNAS, 105:4329-4334, 2008.

189. Bailey CM, Abbott DE, Margaryan NV, Khalkhali-Ellis Z and Hendrix MJC. Interferon regulatory

factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Mol Cell Biol, 28:2235-2243, 2008.

190. Postovit LM, Margaryan NV, Seftor EA, and Hendrix MJC. Role of nodal signaling underlying

melanoma plasticity. Pig Cell Melanoma Res, 21(3):348-357, 2008. 191. Strizzi L, Abbott DE, Salomon DS and Hendrix MJC. Potential for cripto-1 in defining stem cell-like

characteristics in human malignant melanoma. Cell Cycle, 7:1931-1935, 2008. 192. Bailey C and Hendrix MJC. IRF6 in development and disease: A mediator of quiescence and

differentiation. Cell Cycle, 7:1925-1930, 2008. 193. Khalkhali-Ellis Z, Abbott DF, Bailey CM, Goossens W. Margaryan NV, Gluck SL, Reuveni M and

Hendrix MJC. IFN-gamma regulation of vacuolar pH, cathepsin D processing and autophagy in mammary epithelial cells. J Cell Biochem, 105(1):208-218, 2008. (Feature Highlight)

194. Kasemeier-Kulesa JC, Teddy JM, Postovit LM, Seftor EA, Seftor REB, Hendrix MJC and Kulesa

PM. Reprogramming multipotent tumor cells with the embryonic neural crest microenvironment. Dev Dyn, 237(10):2657-2666, 2008.

195. Demou Z and Hendrix MJC. Microgenomics profile of the endogenous angiogenic phenotype in

subpopulations of aggressive melanoma. J Cell Biochem, 105(2):562-573, 2008. (Feature Highlight)

196. Abbott DE, Bailey CM, Postovit LM, Seftor EA, Margaryan NV, Seftor REB and Hendrix MJC. The

epigenetic influence of tumor and embryonic microenvironments: how different are they? Cancer Microenviron, 1:13-21, 2008.

197. Strizzi L, Postovit LM, Margaryan NV, Seftor EA, Abbott DE, Seftor REB, Salomon DS and

Hendrix MJC. Emerging roles of nodal and cripto-1: From embryogenesis to breast cancer progression. Breast Disease, 29:91-103, 2008.

Mary J.C. Hendrix

198. Margaryan NV, Strizzi L, Abbott DE, Seftor EA, Rao MS, Hendrix MJC and Hess AR. EphA2 as a

promoter of melanoma tumorigenicity. Cancer Biol Therapy, 8:275-284, 2009. 199. Strizzi L, Postovit L-M, Margaryan NV, Lipavsky A, Gadiot J, Blank C, Seftor REB, Seftor EA and

Hendrix MJC. Nodal as a biomarker for melanoma progression and a new therapeutic target for clinical intervention. Expert Rev Dermatol, 4:67-78, 2009. (Cover Illustration)

200. Bailey C, Margaryan NV, Abbott DE, Schutte BC, Yang B, Khalkhali-Ellis Z and Hendrix MJC.

Temporal and spatial expression patterns for the tumor suppressor Maspin and its binding partner IRF6 during breast development. Devel Growth Diff, 51:473-481, 2009. (Cover Illustration)

201. Strizzi L, Hardy KM, Seftor EA, Costa FF, Kirschmann DA, Seftor REB, Postovit L-M and Hendrix

MJC. Development and cancer: At the crossroads of Nodal and Notch signaling. Cancer Res, 69(18):7131-7134, 2009.

202. Orgaz JL, Ladhani O, Hoek KS, Fernandez-Barral A, Mihic D, Aguilera O, Seftor EA, Bernad A,

Rodriguez-Peralto JL, Hendrix MJC, Volpert OV and Jimenez B. Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma. Oncogene 28(47):4147-4161.2009.

203. Hamm CA, Xie H, Costa FF, Vanin E, Seftor EA, Sredni ST, Bischof J, Bonaldo MdF, Hendrix

MJC, Soares MB. Global demethylation of rat chondrosarcoma cells after treatment with 5-Aza-2’-deoxycytidine results in increased tumorgenicity. PloS One, 17;4(12):e8340, 2009.

204. Costa FF, Seftor EA, Bischof JM, Kirschmann DA, Strizzi L, Arndt K, Bonaldo M, Soares MB and

Hendrix MJC. Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics 1(2):387-398, 2009.

205. Abbott DE, Margaryan NV, Khan JJS, Kaklamani V, Winchester DJ, Hansen N, Rademaker A,

Khalkhali-Ellis Z and Hendrix MJC. Reevaluating Cathepsin D as a biomarker for breast cancer: Serum activity levels versus histopathology. Cancer Bio Therap 9(1):23-30, 2010.

206. Margaryan NV, Kirschmann DA, Lipavsky A, Bailey CM, Hendrix MJC and Khalkhali-Ellis Z. New

insights into cathepsin D in mammary tissue development and remodeling. Cancer Biol Ther, 10(5):457-466, 2010. (Highlighted on Cover) PMID:20592493

207. Hamm CA, Stevens JW, Xie H, Vanin EF, Morcuende JA, Abdulkawy H, Seftor EA, Sredni ST,

Bischof JM, Want D, Malchenko S, Bonaldo MdeF, Casavant TL, Hendrix MJC and Soares MB. Microenvironment alters epigenetic and gene expression profiles in Swarm rat chondrosarcoma tumors. BMC Cancer 10(1):471, 2010. PMID:20809981.

208. Malchenko S, Galat V, Seftor EA, Vanin EF, Costa FF, Seftor REB, Soares MB and Hendrix MJC.

Cancer hallmarks in induced pluripotent cells: New insights. J Cell Physiol 225(2):390-393, 2010 (Cover Illustration). PMID:20568225.

209. Hardy KM, Booth BW, Hendrix MJC, Salomon DS and Strizzi L. ErbB/EGF signaling and EMT in

mammary development and breast cancer. Mammary Gland Biol Neoplas 15(2):191-199, 2010. (Cover Illustration). PMID:20369376

210. Watanabe K, Meyer M, Strizzi L, Lee J, Gonzales M, Bianco C, Nagaoka T, Farid S, Margaryan N,

Hendrix MJC, Vonderhaar B and Salomon D. Cripto-1 is a cell-surface marker for a tumorigenic

Mary J.C. Hendrix

undifferentiated subpopulation in human embryonal carcinoma cells. Stem Cells 28(8):1303-1314, 2010. PMID:20549704.

211. Hardy KM, Kirschmann DA, Seftor EA, Margaryan NV, Postovit L-M, Strizzi L and Hendrix MJC.

Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 70(24):10340-10350, 2010. (Cover Illustration) PMID:21159651

212. Strizzi L, Hardy KM, Kirsammer GT, Gerami P and Hendrix MJC. Embryonic signaling in

melanoma: potential for diagnosis and therapy. Lab Invest 91:819-824, 2011. PMID:21464823. 213. Lawrence MG. Margaryan NV, Loessner D, Collins A, Kerr KM, Turner M, Seftor EA, Stephens

CR, Lai J, Postovit LM, Clements JA and Hendrix MJC. Reactivation of embryonic Nodal signaling is associated with tumor progression and promotes the growth of prostate cancer cells. Prostate 71(11):1198-1209, 2011. PMID:21229563

214. De Luca A, Lamaura L, Strizzi L, Roma C, D’Antonio A, Margaryan N, Piozzi G, Hsu M-Y, Botti G,

Mari E, Hendrix MJC, Salomon DS and Normanno N. Expression and functional role of Cripto-1 in cutaneous melanoma. Br J Cancer 91:819-24, 2011. PMID:21464823

215. Strizzi L, Hardy KM, Kirschmann DA, Ahrlund-Richter L and Hendrix MJC. Nodal expression and

detection in cancer: Experience and challenges. Cancer Res 72(8):1915-1920, 2012. PMID:22508696

216. Galat V, Malchenko S, Galat Y, Ishkin A, Nikolsky Y, Kosak ST, Soares MB, Iannaccone P,

Crispino J D and Hendrix MJC. A model of early human embryonic stem cell differentiation reveals inter-and intracellular changes upon transition to squamous epithelium. Stem Cells Dev 21(8):1250-1263, 2012. PMID:21861759

217. Malchenko S, Seftor EA, Nikolsky Y, Hasegawa SL, Kuo S, Stevens JW, Poyarkov S, Nikolskaya

T, Kucaba T, Wang M, Abdulkaw H, Casavant T, Morcuende J, Buckwalter J, Hohl R, DeYoung B, Kernstine K, Bonaldo MdeF, Hendrix MJC, Soares MB and Soares VM. Putative multi-functional signature of lung metastases in dedifferentiated chondrosarcoma. Sarcoma, 2012:820254. Epub 2012 Feb 16. PMID:22448124

218. Chen L, Kasai T, Li Y, Sugii Y, Jin G, Okada M, Vaidyanath A, Mizutani A, Satoh A, Kudoh T,

Hendrix MJC, Salomon DS, Fu L and Seno M. A model of cancer stem cells derived from mouse induced pluripotent stem cells. PLoS ONE 7(4):e33544, 2012. PMID:22511923

219. Strizzi L, Hardy KM, Margaryan NV, Hillman DW, Seftor EA, Chen B, Geiger XJ, Thompson EA,

Lingle WL, Andorfer CA, Perez EA and Hendrix MJC. Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer. Breast Cancer Res 14(3):R75, 2012. PMID:22577960

220. Kirschmann DA, Seftor EA, Hardy KM, Seftor REB and Hendrix MJC. Molecular pathways:

Vasculogenic mimicry in tumor cells: Diagnostic and therapeutic implications. Clin Cancer Res

18(10):2726-32, 2012. PMID:22474319

221. Bodenstine TM, Seftor REB, Khalkhali-Ellis Z, Seftor EA, Pemberton PA and Hendrix MJC. Maspin: Molecular mechanisms and therapeutic implications. Cancer Metas Rev 31(3-4): 529-551, 2012. PMID:22752408

Mary J.C. Hendrix

222. Seftor REB, Hess AR, Seftor EA, Kirschmann DA, Hardy KM, Margaryan NV and Hendrix MJC. Tumor cell vasculogenic mimicry: From controversy to therapeutic promise. Am J Pathol 181(4):1115-1125, 2012. PMID:22944600

223. Malchenko S, Bonaldo MdeF, Galat V, Vanin EF, Seftor REB, Hendrix, MJC and Soares MB.

OTX2 is distinctively expressed at the onset of hESC neuronal differentiation. Stem Cells, in press, 2013.

224. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, Lu C, Nagaraja AS, Gharpure KM, Kang Y, Rodriguez-Aguayo C, Vivas-Mejia PE, Zand B, Schmandt R, Wang H, Langley RR, Jennings JB, Ivan C, Coffin JE, Armaiz GN, Bottsford-Miller J, Kim SB, Halleck MS, Hendrix MJC, Bornman W, Bar-Eli M, Lee JS, Siddik ZH, Lopez-Berestein G, Sood AK. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 123(5):2119-2130, 2013. PMID:23585472

225. Tysnes BB, Sætran HA, Mørk SJ, Margaryan NV, Geir EE, Petersen K, Strizzi L and Hendrix

MJC. Age dependent association between protein expression of the embryonic stem cell marker Cripto-1 and survival of glioblastoma patients. Translational Oncology, in press, 2013.

226. Jamil S, Cedervall J, Hultman I, Ali R, Margaryan NV, Rasmuson A, Johnsen JI, Sveinbjörnsson B, Dalianis T, Kanter L, Orrego A, Strizzi L, Hendrix MJC, Sandstedt B, Kogner P and Ahrlund-Richter L. Neuroblastoma cells injected into experimental mature teratoma reveal a tropism for embryonic loose mesenchyme. Int J Oncol 43(3):831-838, 2013. PMID:23857308

227. Strizzi L, Margaryan NV, Gilgur A, Hardy KM, Normanno N, Salomon DS and Hendrix MJC. The

significance of a Cripto-1 positive subpopulation of human melanoma cells exhibiting stem cell-like characteristics. Cell Cycle 12(9):1450-1456, 2013. PMID:23574716

228. Malchenko S, Xie J, Bonaldo MdF, Vanin EF, Galat V, Goossens W, Seftor REB, Crispino J, Miller RJ, Bohn MC, Hendrix, MJC and Soares MB. Onset of rosette formation during spontaneous neural differentiation of hESC and hiPSC colonies. Gene, Aug 15. Doi:pii.S0378-119(13)01009-3. 10.1016/j.gene.2013.101 [Epub ahead of print], 2013. PMID:23954875

229. Tysnes BB, Sætran HA, Mørk SJ, Margaryan NV, Geir EE, Petersen K, Hendrix MJC and Strizzi

L. Age dependent association between protein expression of the embryonic stem cell marker Cripto-1 and survival of glioblastoma patients. Translational Oncol 6(6): 732-741, 2013. PMID:24466376

230. Seftor EA, Seftor REB, Weldon D, Kirsammer GT, Margaryan NV, Gilgur A and Hendrix MJC.

Melanoma tumor cell heterogeneity: A molecular approach to study subpopulations expressing the embryonic morphogen Nodal. Seminars in Oncology, [Epub Feb 7.2014], Apr;41(2):259-66. doi: 10.1053/j.seminoncol.2014.02.001.

231. Yan T, Mizutani A, Chen L, Takaki M, Hiramoto Y, Matsuda S, Shigehiro T, Kasai T, Kudoh T,

Murakami H, Masuda J, Hendrix MJC, Strizzi L, Salomon DS, Fu L, Seno M. Characterization of cancer stem-like cells derived from mouse induced pluripotent stem cells transformed by tumor-derived extracellular vesicles. J Cancer 2014; 5(7):572-584. doi:10.7150/jca.8865.

232. Khalkhali-Ellis Z, Goossens W, Margaryan NV, Hendrix MJC. Cleavage of Histone 3 by Cathepsin D in the involuting mammary gland. PLOS ONE, 2014, in press.

Mary J.C. Hendrix

233. Khalkhali-Ellis Z and Hendrix MJC. Two faces of Cathepsin D: Physiological guardian angel and pathological demon. Biology and Medicine, 2014, in press.

234. Khalkhali-Ellis Z, Kirschmann DA, Seftor EA, Gilgur A, Bodenstine T, Hinck AP, Hendrix MJC. Divergence(s) in Nodal signaling between aggressive melanoma and embryonic stem cells. Int J Cancer, 2014, in revision.

235. Bodenstine TM, Seftor RE, Seftor EA, Khalkhali-Ellis Z, Samii NA, Monarrez JC, Chandler GS,

Pemberton PA, Hendrix MJ. Internalization by multiple endocytic pathways and lysosomal processing impact Maspin-based therapeutics. Mol Cancer Research, 2014, in press.

236. Kirsammer G, Strizzi L, Margaryan NV, Gilgur A, Hyser M, Atkinson J, Kirschmann DA, Seftor EA,

Hendrix MJC. Nodal signaling promotes a tumorigenic phenotype in human breast cancer. Semin Cancer Biol, 2014, in press.

B. Books, Book Chapters and Invited Commentaries 1. Hendrix MJC and Fulginiti VA. The Arizona Disease Control Research Commission. Arizona Med.

45:8, 1985. 2. Lotan R, Hendrix MJC and Lippman SM. Retinoids in the management of melanoma. Retinoids

and Cutaneous Malignancy, edited by R. Marks. Oxford: Backwell Scientific Publications, pp. 133-149, 1991.

3. Lymphology, Washington, D.C. September 20-26, 1993. Edited by M.H. Witte and C.L. Witte.

The International Society of Lymphology, Zurich, Switzerland and Tucson, AZ, USA, Lymphology 27 (Suppl.) 401-403, 1994.

4. Seftor EA, Seftor REB, Way DL, Bernas M, Weinard CL, Witte CL and Hendrix MJC.

Enhancement of endothelial cell and Kaposi sarcoma migration by selective chemoattractants. Progress in Lymphology XIV. Proceedings of the 14th Internation Congress of Lymphology, Washington, D.C. September 20-26, 1993. Edited by M.H. Witte and C.L. Witte. The International Society of Lymphology, Zurich, Switzerland and Tucson, AZ, USA, Lymphology 27 (Suppl.) 755-758, 1994.

5. Lymphology XIV. Proceedings of the 14th Internation Congress of Lymphology, Washington, D.C.

September 20-26, 1993. Edited by M.H. Witte and C.L. Witte. The International Society of Lymphology, Zurich, Switzerland and Tucson, AZ, USA, Lymphology 27 (Suppl.) 138-141, 1994.

6. Sager R, Sheng S, Anisowicz A, Sotiropoulou G, Stenman G, Swisshelm K, Chen Z, Hendrix

MJC, Pemberton P, Rafidi K and Ryan K. In: RNA genetics of breast cancer: MASPIN as a paradigm. Cold Spring Harbor, FYMP Quant. Biol. 59:537-546, 1994.

7. Sager R, Sheng S, Pemberton P and Hendrix MJC. Maspin: A tumor suppressing gene. In:

Current Topics in Microbiology and Immunology; Attempts to Understand Metastasis Formation I, edited by U Gunthert and W Birchmeier. Berlin: Springer-Verlag, 213:51-64, 1996.

8. Hendrix MJC, Seftor EA, Chu Y-W, Trevor KT and Seftor REB. Role of intermediate filaments in

migration, invasion and metastasis. In: Cancer and Metastasis Reviews, edited by P Frost, I Hart and R Kerbel. Netherlands: Kluwer Academic Publishers 15:507-525, 1997.

Mary J.C. Hendrix

9. Seftor REB, Seftor EA and Hendrix MJC. Molecular role(s) for integrins in human melanoma invasion. In: Cancer Metastasis Reviews, edited by M Bar-Eli. Netherlands: Kluwer Academic Publishers 18:359-375. 2001.

10. Hendrix MJC, Seftor EA and Seftor REB. Membrane Invasion Culture System. In: Methods in

Molecular Medicine, Metastasis Research Protocols, vol 2, edited by S Brooks and U Schumacher. USA: Humana Press 58:71-79, 2001.

11. Seftor EA, Hess AR, Meltzer PS, Schatteman GC, Gruman LM, Kirschmann DA, Seftor REB and

Hendrix MJC. Tumor cell plasticity allows for vasculogenic mimicry by aggressive melanoma. In: Basic and Clinical Research on Tumor Markers, edited by JC Barrett, K Imai, T Kakizoe, JE Shively and K Yamaguchi. Tokyo: Princess Takamatsu Cancer Research Fund, 2001.

12. Kirschmann DA and Hendrix MJC. Heterochromatin-associated protein 1, HP1Hsα, in breast

cancer invasion and metastasis. In: Cancer Metastasis-Related Genes, edited by D Welch. Netherlands: Kluwer, pp. 173-192, 2002.

13. Seftor REB, Odero VA, Seftor EA and Hendrix MJC. Maspin suppresses breast cancer cell

invasiveness by modulating integrin expression and function. In: Maspin, edited by MJC Hendrix. USA: Landes Bioscience Publishers, 32:84-92, 2002.

14. Dokras A, Gardner LMG, Kirschmann DA, Seftor EA and Hendrix MJC. The role of maspin in

human placental development. In: Maspin, edited by MJC Hendrix. USA: Landes Bioscience Publishers, 32:119-123, 2002.

15. Hendrix MJC. (Editor) Maspin. USA: Landes Biosciences Publishers, 32, 2002. 16. Hendrix MJC. Philosophical Views: The changing complexion of America's academic research

enterprise. Cancer Biology & Therapy, 1:5, 568-570, 2002. 17. Hendrix, MJC. Apoptosis in colorectal tumors: does it help tumors metastasize? In: Cancer

Biology & Therapy, 1:64, 2002a. 18. Hendrix MJC, Seftor EA, Kirschmann DA, Quaranta V and Seftor REB. Remodeling of the

microenvironment by aggressive melanoma tumor cells. In: Annals NY Acad Sci, 995:151-161, 2003.

19. Hendrix MJC, Luo J, Seftor EA, Sharma N, Heidger PM Jr, Cohen MB, Bhatty R, Chunthapong J,

Seftor REB and Lubaroff DM. Epithelial-mesenchymal molecular interactions in prostatic tumor cell plasticity. In: Cancer Metastasis – Biology and Treatment, edited by RL Ablin and MD Mason, Netherlands, Kluwer Academic Publishers, 2003.

20. Hendrix MJC, Seftor EA, Meltzer PS, Hess AR, Gruman LM, Nickoloff BJ, Miele L, Sheriff DD,

Schatteman GC, Bourdon MA and Seftor REB. The stem cell plasticity of aggressive melanoma tumor cells. In: Germinal Stem Cells, (E.S. Sell, ed.), Humana Press, USA, pp. 297-306, 2004.

21. Seftor EA, Meltzer PS, Kirschmann DA, Margaryan NV, Seftor REB and Hendrix MJC. The

epigenetic influence of the tumor microenvironment on melanoma cell plasticity. In: Integration/Interaction of Oncologic Growth, (G.G. Meadows, ed.), Netherlands: Springer Publishers 15:47-63, 2005.

Mary J.C. Hendrix

22. Hendrix MJC, Seftor EA and Seftor REB. The plasticity of melanoma cells and associated clinical implications. In: From Melanocytes to Malignant Melanoma, (V Hearing, SPL Leong, eds.) Humana Press, USA, 2005.

23. Hendrix MJC, Seftor EA and Seftor REB. Vasculogenic mimicry: angiogenesis in disguise? In:

Frontiers in Angiogenesis, (R. Forough, ed.), Springer, Dordrecht, The Netherlands, 97-109, 2006. 24. Hess AR and Hendrix MJC. Focal adhesion kinase signaling and the aggressive melanoma

phenotype. Cell Cycle (Extra-views), 5(5):478-480, 2006. 25. Hendrix MJC, Luo J, Seftor EA, Sharma N, Heidger PM Jr, Cohen MB, Bhatty R, Chunthapong J,

Seftor REB and Lubaroff DM. Epithelial-mesenchymal molecular interactions in prostatic tumor cell plasticity. In: Metastasis Cancer of Prostate, (RL Ablin and MD Mason, ed.), Springer, The Netherlands, 10:127-141, 2007.

26. Seftor REB, Seftor EA, Postovit LM and Hendrix MJC. In: Cancer Metastasis: From Local

Proliferation to Distant Sites Through the Lymphovascular System, (SLP Leong, ed.), Springer, The Netherlands, 2008.

27. Postovit LM, Margaryan NV, Seftor EA, Strizzi L, Seftor REB and Hendrix MJC. Plasticity

underlying multipotent tumor stem cells. In: Stem Cells and Cancer, (RG Bagley and BA Teicher, ed.), USA: Humana Press, 2008 (Cover Illustration).

28. Khalkhali-Ellis Z, Zhang M and Hendrix MJC. Maspin and Cathepsin D partnership in regulating

mammary gland development and breast cancer. In: Breast Cancer: Causes, Diagnosis and Treatment, (MR Romero, ed.), USA: Nova Science Publishers, Inc., 2009.

29. Hendrix MJC. Forward: Charting a course to a distant site. Nature Rev Cancer 9:237, 2009. 30. Telerman A, Amson R and Hendrix MJC. Tumor reversion holds promise. OncoTarget 1(4):233-

234, 2010.

31. Strizzi L, Hardy KM, Seftor EA, Margaryan NV, Kirschmann DA, Kirsammer GT, Bailey CB, Kasemeier-Kulesa JC, Kulesa PM, Seftor REB and Hendrix MJC. Lessons from Embryogenesis. In: Melanoma Development, (A. Bosserhoff, ed.), Springer-Verlag/Wien, pp. 281-296, 2011.

32. Strizzi L, Hardy KM, Bodenstine TM and Hendrix MJC. Targeting the stem cell plasticity of tumor

cells. In: Stem Cells Handbook (E.S. Sell, ed.), Humana Press, USA, pp.441-448, 2013.

C. Published Abstracts - available upon request D. Awarded Patents (Licensing in progress)

Diagnostics and Therapeutics of Vascular Mimicry (US 6524787)

Nodal as a Therapeutic Target (US 7666423)

Lefty as a Cancer Therapy (US 8106004)

Nodal as a Diagnostic Biomarker (US 7666423)

Mary J.C. Hendrix

Targeting Notch4 as a Regulator of Nodal (US 8669239)

Developing therapeutics to target Nodal and Notch4 (AUS 279205)

E. Submitted Patent Applications - available upon request

Curriculum Vitae: MARY J.C. HENDRIX July 2014 US...

Documents

Transcript of Curriculum Vitae: MARY J.C. HENDRIX July 2014 US...